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Abstract: Human immunodeficiency virus type 1 (HIV-1) is responsible for the majority of HIV
infections worldwide, and we still lack a cure for this infection. Blocking the interaction of HIV-1 and
its primary receptor CD4 is one strategy for identifying new anti-HIV-1 entry inhibitors. Here we
report the discovery of a novel ligand that can inhibit HIV-1 entry and infection via CD4. Biological
and computational analyses of this inhibitor and its analogs, using bioactivity evaluation, Rule
of Five (RO5), comparative molecular field analysis (CoMFA)/comparative molecular similarity
index analysis (CoMSIA) models, and three-dimensional quantitative structure-activity relationship
(3D-QSAR), singled out compound 3 as a promising lead molecule for the further development of
therapeutics targeting HIV-1 entry. Our study demonstrates an effective approach for employing
structure-based, rational drug design techniques to identify novel antiviral compounds with
interesting biological activities.
Keywords: HIV-1; entry inhibitor; CD4; virtual screening; 3D-QSAR
1. Introduction
Acquired immune deficiency syndrome (AIDS) is one of the major diseases of large public health
impact. It is caused by HIV, and it represents the final stage of HIV infection [1]. One of the hallmarks
of HIV infection is the selective destruction of CD4 T-cells [2]. Treatment for patients infected with
HIV is usually antiretroviral therapy (ART), with double or triple drug combinations chosen from
approved drugs [3,4]. The viral entry process is one of the most promising targets for the development
of new anti-HIV drugs effective in the virus replication cycle for the long-term treatment of patients
with AIDS [5,6]. Two types of HIV are recognized, HIV-1, which is responsible for the majority of
HIV infections worldwide, and HIV type 2 (HIV-2), which causes the infection endemic in western
Africa [7,8]. Here, our work mainly focuses on the worldwide infection caused by HIV-1.
CD4, as the primary receptor of the HIV-1 envelope glycol protein 120 (gp120), is critical for
HIV-1 entry into host cells [9,10]. HIV-1 infection is initiated by the binding and attachment of gp120
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to CD4 [11], which induces a series of conformational changes in gp120 that consequently expose
its third variable (V3) loop for specific recognition of a coreceptor, either CCR5 or CXCR4 [12–14].
Coreceptor binding is the second obligatory event in HIV-1 entry, and it can specifically determine
the tropism of HIV-1 infection [15,16]. Following the interaction of viral gp120 with its coreceptor, the
gp120-gp41 complex undergoes a dramatic conformational change that leads to the formation of a
trimeric hairpin structure of gp41, enabling the viral envelope to fuse with the host cell membrane.
As a result, the viral capsid is released into the cytoplasm of the target host cell [17,18]. HIV-1 infection
induces a progressive and quantitative decline in CD4+ T cell responses, and this finally leads to
AIDS [19].
The interaction between CD4 and gp120 has been studied by mutagenesis and crystal
structure determination to identify the CD4 residues that are implicated in gp120 binding [10,20,21].
The published data indicate that residues 29, 35, and 40–48 of CD4 are critical for the
recognition of HIV-1 gp120 [22]. These residues form a region that is homologous to the second
complementarity-determining region (CDR2) of immunoglobulin light chains [23]. In this interaction
between CD4 and gp120, 63% of all interatomic contacts come from residues 40–48 of CD4, and Phe43
alone accounts for 23% of the total contacts [21].
These known interactions suggest that blocking the interaction of CD4 and gp120 could be a
promising way to inhibit HIV-1 entry into its host cell. Three strategies are possible for the discovery of
new anti-HIV drugs that work by blocking the interaction of CD4 and gp120 [24]. One is discovering
new agents that can bind to gp120 and prevent the gp120/CD4 interaction. BMS (Bristol-Myers
Squibb)-378806 (BMS-806) and NBD-556 are two representative small molecules [25]. BMS-378806
inhibits the interaction of gp120/CD4 and HIV infection at a nanomolar level [26]. Among the
BMS family, BMS-663068, the prodrug of BMS-626529, was a more promising inhibitor that showed
improved in vitro and pharmacokinetic properties and it is being assessed in a Phase III clinical
trial [27,28]. Conversely, NBD-556 and its analogs, as CD4-mimics, were designed to target the Phe43
cavity of gp120 [29,30], thereby, inhibiting the gp120/CD4 interaction and HIV-1 infection. The initial
lead compounds of this series, NBD-556 and NBD-557, were screened from a small molecule library
and identified using a syncytium formation assay [31]. A further development of the NBD series,
NBD11021, showed a more promising level of anti-HIV activity [32] when compared with other
compounds presenting anti-HIV-1 activity, like the DMJ and JRC series compounds [33,34].
Because of the high rate of mutagenesis of gp120, drug resistance becomes one of the key
problems to consider during the development of anti-HIV-1 therapeutic medicines [35], and it becomes
unavoidable when searching for new potential leads targeting gp120. When drug resistance occurs,
and especially cross-resistance, the ART drugs that share the same mechanism of action will be
rendered ineffective. Thus, another strategy for the discovery of HIV-1 entry inhibitors, is to target
CD4, the primary receptor of gp120. PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that
bind to CD4, thereby blocking gp120/CD4 interaction with nanomolar affinities, and they showed
anti-HIV-1 activity [36]; NSC13778 was another gp120/CD4 inhibitor that competed with gp120
for binding to the D1/D2 domain of the CD4 protein with a low micromolar anti-HIV-1 activity;
NSC13778 was screened out using a cell-based anti-HIV-1 screen [37]. Another representative drug is
ibalizumab, an FDA-approved ART drug for multi-drug resistant HIV. Ibalizumab is a humanized
monoclonal antibody that binds to the D2 domain of CD4 with significant anti-HIV-1 activity and
minor adverse effects [38,39]. Ibalizumab cannot directly block the gp120/CD4 interaction, but it
induces conformational changes in the CD4-gp120 complex and prevents HIV entry [39].
The third strategy is downmodulation of CD4 and prevention of HIV entry. The representative
compound is cyclotriazadisulfonamide (CADA), a small molecule that can decrease the amount of cell
surface and intracellular CD4, thereby resulting in anti-HIV-1 activity [40].
In our manuscript, our strategy for discovery of new HIV-1 entry inhibitors was focused on a
relatively conserved target, CD4, the primary receptor of gp120, which avoids much of any future
concern about drug resistance [41]. A structure-based and computer-aided virtual screening (VS)
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approach, which searches chemical libraries to discover compounds that can interact with a protein
structure with predicted binding affinities and modes, is one of the most powerful methods for
identifying new inhibitors [42,43]. This approach is becoming increasingly important and effective for
new drug discovery [44].
In this paper, we aimed to design novel non-peptide CD4 ligands based on the 3D structure of the
CD4 protein. We conducted a VS study by targeting the critical amino acid residues on CD4 using
Flex-Dock function of SYBYL-X program to identify compounds from the National Cancer Institute
(NCI) structure diversity data set, a library consisting of 1974 compounds with diverse chemical
structures that were predicted to bind the CD4 target. We collected 40 top-binding compounds
predicted by VS and determined their actual CD4 antibody competitive binding affinities. Among the
40 compounds, compound 3 (NSC119915, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl) propanoic acid)
had the best CD4 competitive binding with an IC50 value of 45 µM. As CD4 is essential in the process
of HIV-1 entry into host cells, HIV-1 entry inhibition assays were also performed for this most potent
compound. HIV-1-infected groups treated with 3 showed inhibition of viral replication, indicated by a
decrease in both green fluorescent protein (GFP) fluorescence and intracellular p24 level as compared
with those of untreated groups. The IC50 values for these two measurements were 10 and 9 µM,
respectively, indicating that 3 was able to suppress HIV-1 infection by inhibiting the viral entry process.
Based on the discovery of 3, we further examined 40 additional compounds of chemical structures
that were similar or related to 3, which were selected by the NCI database browser. This identified
another new anti-HIV-1 compound 29. A previously published paper by Robert J. Fisher et al.
presented the result that 29, generated from biological high-throughput screening using a robotic
system, could bind to HIV-1 nucleocapsid-p7 protein (NC-p7), which is crucial in promoting reverse
transcription [45,46] and could inhibit HIV-1 infection [45]; however, 3 was inactive or weakly active
(0–49% protection) when evaluated in their anti-HIV-1 infection assays. Taken together, the results
from our present study and from Fisher’s previous report indicate that 3 and 29 could act as potential
dual-target HIV-1 inhibitors. CD4 competitive binding assays, in conjunction with 3D-QSAR studies,
were performed on these compounds. The bioassay data were used to construct CoMFA and CoMSIA
models with excellent parameters [47,48].
Taken together, the results from CD4 competitive binding and anti-HIV-1 infection assays showed
that 3 is a promising new lead compound for the effective inhibition of HIV-1 entry via CD4. Our
3D-QSAR studies based on 3 also provide a deeper insight into the interaction of CD4 and its newly
discovered ligands, and reliable 3D-QSAR models that can guide the optimization of the chemical
structure of the lead compound.
2. Results
2.1. Virtual Screening
The binding site of CD4, which is a hydrophobic cavity (Figure 1A) located near the critical amino
acid sequences (40–48) for CD4 and gp120 interaction, was used as the target site to perform VS on the
NCI diversity data set. Of the 1974 compounds docked, 40 top-score compounds were selected and
analyzed for the interaction between the receptor and ligands. Five compounds showed CD4 binding
activities and could form three or four H-bonds, which play an important role in ligand binding.
These compounds were predicted to recognize the reported critical amino acid residues such as Asn39,
Gln40, Thr45, and Gly47, which contribute to the interaction between CD4 and gp120.
2.2. Competitive CD4-Binding Compounds
We chose CD4-expressing SUP-T1 cells to perform the competitive CD4 binding assay.
Non-labeled anti-human CD4 antibody (RPA-T4 clone, BioLegend, San Diego, CA, USA) was used as
a positive control. We found that five compounds collected from the NCI diversity dataset had CD4
competitive binding activities (Table 1, Figure 1B).
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Among the five compounds, 3 showed the best inhibition in this assay (Figure 1B). The docking
model demonstrated that 3 could bind to the CD4 D1 CDR3-CC′ pocket [49] (Figure 1C) and form
H-bond with residues Asn39, Thr45, and Gly47, which are critical in the interaction of CD4 and gp120
(Figure 1D). In addition, this compound also has Van der Waals (vdW) contacts with the CD4 receptor.
The CD4 competitive binding inhibition of 3 at 100 µM was 94.94%, and the IC50 value was 45 µM
(Figure 1E).
We also performed a cell viability assay to test the potential cytotoxicity of 3. In parallel with
the competitive CD4 binding assay described above, the same densities of SUP-T1 cells were seeded
and treated with the test compounds for the same duration. Compound 3 showed no cytotoxicity
in the cell viability assay, even when used at a much higher concentration (200 µM) than that used
in the competitive CD4 binding assays (Figure 1F). These data demonstrated that compound 3 is a
CD4-binding lead compound of no cytotoxicity.
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Table 1. The structures and inhibition of five bioactive compounds from the National Cancer Institute
(NCI) dataset.
No. NSC No. Structure Inhibition at 100 µM (%)
1 14410
Molecules 2018, 23, x 5 of 19 
 
Table 1. The structures and inhibition of five bioactive compounds from the National Cancer Institute 
(NCI) dataset. 
No.  . Str ct r  In i iti  at 1 0 μM (%) 
1  
 
34.22 
2 34238 
 
36.86 
3 119915 
 
94.94 
4 123526 
 
22.61 
5 268665 
 
33.09 
2.3. NSC119915 Displayed Potent Anti-HIV-1 Activity 
We performed anti-HIV-1 infection and anti-HIV-1 entry assays by measuring GFP expression 
and intracellular p24 antigen level. For the anti-HIV-1 infection assays, the CEM-GFP reporter cell 
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1 infected group, with an IC50 value of 10 µM (Figure 2A). This indicated that 3 could inhibit HIV-1 
infection.  
We also performed anti-HIV-1 entry assays to investigate the potential suppression by 3 of HIV-
1 infection via its entry mechanism. Peripheral blood mononuclear cells (PBMCs) that were infected 
with HIV-1 (NL4-3 strain) for 24 h showed a decrease in their intracellular p24 antigen levels after 
treatment with 3, as well as dose-dependent HIV-1 inhibition with an IC50 value of 9 μM (Figure 2C). 
The inhibition by a positive control compound AMD3100 at 0.1 μM was 57.6% (Figure 2B). These 
data further demonstrated that 3 acted as an HIV-1 entry inhibitor.  
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2.4. NSC119915 Showed No Cytotoxicity in PBMCs
We employed a cell viability assay to test the potential cytotoxicity of 3. In parallel with the
anti-HIV-1 assay described above, the same densities of PBMCs were seeded and treated with the test
compounds for the same duration. 3 showed no cytotoxicity in PBMCs, even when tested at a higher
concentration (150 µM) than that used in the competitive CD4 binding assay (Figure 2D).
2.5. Bioactivity Evaluations of Compounds Collected from Structural Similarity Screening
We performed a similarity search study using the Enhanced NCI Database Browser 2.2 to select
40 compounds from a total of 250,250 compounds with a Tanimoto index of above 90%, and obtained
them from NCI. The Tanimoto index is a useful tool for 2D fragment-based similarity searching [51].
The competitive CD4 binding assay showed that compounds 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29,
and 32 had better CD4 competitive binding affinities than other compounds, as their inhibitions at
100 µM were all above 20% (Figure 3A). The binding inhibition and compound structures are showed
in Table 2 and Figure 3A. Among these compounds, 29 (Figure 3B) showed the best binding affinity
when compared to the other compounds, and its chemical structure was quite similar to that of 3.
The binding inhibition of 29 in the anti-human CD4 antibody competitive binding assays was 85.29%
at 100 µM, and the IC50 value was 14 µM (Figure 3C).
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confir ed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was not due to cytotoxic
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead co pound
for developing ne ligands to inhibit IV-1 infection via CD4.
ost of the co pounds collected fro CI database using the si ilarity search approach share
certain co on substructures ith 3. These co pounds ere classified into four classes for further
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are shown
in Table 2.
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Table 2. The structures and inhibition data of compounds generated from the NCI similarity search.
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effect (E). 
We also evalu ted the anti-HIV-1 infect on activity of 29 using the CEM-GFP r porter cell line. 
The GFP values were significantly ower for HIV-1 i fected groups treated with 29 than the group 
without drug treatment, and decr as  f the GFP values w re dose-depend nt, indicati g that 29 
w s an effective HIV-1 inhibitor identified by similarity s a ch using 3 as a lead template. The C50 
value of 29 was 2 µM (Figure 3D), nd 29 s owed no cytotoxicity, s det rmine  by the cell vi bility 
i  the CEM-GFP cell line, whe  tested at the highest conce tra o  of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and tha  its a t -HIV-1 activity was not due to cytotoxi
effect  on the host cells. These bioactiv y data also provide vidence that 3 i  a viable lea  compound 
for developing new ligands to inhib t HIV-1 infection via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each cl ssification and CD4 bindi g inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
 
     8.87 
olecules 2018, 3, x 7 of 19 
 
 
Fig re 3. he co etitiv  4 bin ing assay res lts of analogs of 3 ( ). ong these analogs, 29 
sho e  th  best bin ing aff nity h an I 50 v l e of 14 µ  ( , ). 29 inhib te  I -1 infection in a 
ose- e n ent a ner ( ), an  a ell r l e ass y of 29 sho e  a co lete lack of yt toxici y 
effect ( ). 
e als e al ate  t  a ti- I 1 i fecti  acti it  f 29 si  t e -  re ter cell li e.
e  al es re si if ca tl  l er f r I -1 i fecte  r s treate  it  29 t a  t e r  
it  r  t e t t, a  t e ecrease f t e al es r  se- e e e t, i icati  t at 29 
as a  effecti  I -1 i i it r i e tifie   si ilarit  searc  si  3 a a l a t late.  I 50 
al e f 29 as 2  ( i re 3 ), a  29 s e   c t t xicit , as eter i e   t e cell ia ilit  
i  t e -  cell li e, e  teste  a  t e i est c ce tra i  f 25  ( i re 3 ). es r lts 
c fir e  t at 29 is a te t I -1 i i it r, a t at it  a i- I 1 acti it  as t t  c t xic 
effects  t e st cells. ese i act it a a als  r i e e i e ce t at 3 is a a le lea c  
f r e el i  e li a s t  i i it I -1 i fecti  ia 4.  
st f t e c s c lle te  fr  I ata ase si  t e si ilarit  searc  pr ac  s are 
certai  c  s str ct res it  3. se c s ere classifie  i t  f r classes f r f rt er 
st ies. e  str ct res f eac classificat  a 4 i i  i iti  at 100  are 
s  i  a le 2. 
a le 2. he str ct e  an  inhib tion ata of co o n s generate  fro the I si ilarity search. 
lass I:  
 
.  . 1 2 3 4 5 6 
I i iti  at 
100  ( ) 
6 5302       5.64 
7 11840 
 
     8.87 
Mo cules 2018, 23, x 7 of 19 
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showed the best b ding affinity with n IC50 value 14 µM (B,C). 29 nhibited HIV-1 i fection in a 
dos -depe dent ma ner (D), and a CellTiter Blue ssay of 29 sh wed a complete lack of ytotoxicity 
effect (E). 
We also ev luated the anti-HIV-1 infection activity of 29 using the CEM-GFP reporter cell line. 
The GFP values w re s gnificantly low r f r HIV-1 inf cted groups tr ated with 29 than the group 
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Figure 3. The competitive CD4 bindi g as ay results of anal gs of 3 (A). Among these analogs, 29 
show d the est bi di g af inity with n IC50 value of 14 µM (B,C). 29 i hibited HIV-1 infection in a 
ose- epen ent m n r (D), nd a CellTiter Blue assay of 29 sh wed a c mplete lack of cytotoxicity 
eff ct (E). 
W lso evaluated th  an i-HIV-1 infectio activity of 29 using th CEM-GFP reporter cell line. 
Th  GFP v ues wer  sign ficantly low r for HIV-1 infec  groups t e t d w th 29 than the group 
withou  rug r tment, and t e d cr s of th  GFP values were ose-depe en , indic ing that 29 
was a  effect ve HIV-1 inhi or i entif ed by mil rity se rch u ing 3 s a lead template. The IC50 
valu of 29 was 2 µM (Figur 3D), and 29 sh wed no y otoxicit , as d termin d by the cell viability 
in th  CEM-GFP cell li , when ested at the high t concentration of 25 µM (Figure 3E). These results 
co firmed that 29 is p tent HIV-1 i hibitor, a d that an i-HIV-1 activity was n t due to ytotoxic 
eff cts  the host ells. These bioact ity data also pro ide viden  th t 3 is a viable lead compound 
f r developi  new l ga ds to inhibit HIV-1 infection via CD4.  
Most of the co p unds coll cted from NCI datab se u ing the similarity sea ch approach share 
certain common s bstructures with 3. The  compounds were classified into our classes fo  further 
st dies. The common stru tures f each class f cat on and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluated the anti-HIV-1 i fection activity f 29 usi g the CEM-GFP reporter cell line. 
The GFP values were signific ntly lower for HIV-1 infected groups tr ated with 29 than t e gr up 
wit out drug treatme t, and the decre se of th  GFP valu s w re dose-dependent, indicati g that 29 
was an ffective HIV-1 inhibitor ide tified by simil rity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figur  3D), and 29 showe  no cytotoxicity, as d termined y the cell viability 
in th  CEM-GFP cell line, when tested at the highest concentration of 25 µM (Figure 3E). Thes  results 
confirmed that 29 is a potent HIV-1 inhibitor, and th t its anti-HIV-1 activity was not due t  cytotoxic 
effects on the host cells. T es  bioactivity data also pr vide evidence that 3 is a viable l ad c  
for veloping new ligands to inhibit HIV-1 infection vi  CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 bi ing inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitiv  CD4 binding assay r sults of analogs f 3 (A). Among these analogs, 29 
showed the b st binding affi ity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
ose-dependent manner (D), a  a CellTiter Blue assay of 29 showed a complete lack of cytot xicity 
effect (E). 
We also evaluated the anti-HIV-1 infection activity of 29 using the CEM-GFP reporter cell line. 
The GFP values were significantly lower for HIV-1 infected groups tr ated with 29 than the group 
wit out drug treatme t, and the decre se of the GFP values were dose-dependent, indicating that 29 
was an ffective HIV-1 inhibitor ide tified by simil rity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figur  3D), and 29 showed no cytotoxicity, as determined y the cell viability 
in th  CEM-GFP cell line, when tested at the highest concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and th t its anti-HIV-1 activity was not due t  cytotoxic 
effects on the host cells. Thes  bioactivity data also provide evidence that 3 is a viable lead c mpound 
for veloping new ligands to inhibit HIV-1 infection vi  CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
hown in Table 2. 
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Figure 3. The competitiv  CD4 binding assay results of analogs of 3 (A). Amo g these analogs, 29 
showed the best binding affi ity with an IC50 value of 14 µM (B,C). 29 i hibited HIV-1 infection in a 
dose-depe dent ma ner (D), and a CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluated the n -HIV-1 infectio  activity of 29 using the CEM-GFP reporter cell line. 
The GFP values e significantl  l wer f r HIV-1 inf cted groups tr ated with 29 than the group 
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in the CEM-GFP cell line, h n tested at the highest c ncentration of 25 µM (Figure 3E). These results 
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Figure 3. The competitive CD4 binding assay results of l s of 3 (A). Among these analogs, 29 
showed the best binding affinity with  IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
ose-dependent m nner (D), and a CellTiter Blu  assay of 29 sh wed a complete lack of cytotoxicity 
effect (E). 
W  also valuated th  a ti- I -1 inf ction activity of 29 using the CEM-GFP reporter cell lin . 
The GFP values re significantly lower for HIV-1 infect d groups tr ated with 29 than the group 
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was an ffective HIV-1 inhibi o  i e tif d by simil rity se rch u ing 3 s a lead template. The IC50 
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shown in able 2. 
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Figure 3. The competitive CD4 bindi g ass y results of alogs of 3 (A). Among th se analogs, 29 
showed the best bin ing affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-d pendent manner (D), and  CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluat d th  anti-HIV-1 nfection activi y of 29 using the CEM-GFP r porter cell line. 
The GFP valu s were significantly l wer f r HIV-1 infec d groups tr at d with 29 than the group 
wit out drug treatm t, and t e d cre s  of he GFP values were dose- epe d nt, indicating that 29 
was n ffective HIV-1 inhibitor ide tif ed by simil rity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figur  3D), a d 29 sh w d o cytotoxicity, as det rmined y he cell viability 
in th  CEM-GFP c ll line, whe  tested at th  highest concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, a d t t its n i-HIV-1 activity was n t due t  cytotoxic 
effe ts on t  host cells. Thes  bi activity data also provide evidence that 3 is a viable lead c mpound 
for veloping n w ligands to i h b t HIV-1 infectio  vi  CD4.  
Most of the compounds collected from NCI database us ng the similarity search approach share 
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shown in Table 2. 
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Figure 3. The competitiv  CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTit r Blue ssay f 29 s ow  a complete lack of cy ot xicity 
effect (E). 
We also evaluated the nti-HIV-1 inf c on activity of 29 usi g the CEM-GFP r porter cell lin . 
The GFP values were signific ntly lo er for HIV-1 nfected group  treated with 29 th n the gr up 
without drug treatmen , a d the decrease of th  GFP va u  w re do -depend t, ndicating that 29
was an effective HIV-1 inhibitor ident fied by imilarity s arch using 3 s a lead t mpl e. The IC50 
value of 29 was 2 µM (Figur  3D), and 29 how d no cytotoxicity, s d termin d by the c ll viabil ty 
in the CEM-GFP cell line, wh n tested at th  highest concentra on o  25 µM (Figure 3E). Thes  results 
confirmed that 29 is a potent HIV-1 inhibi or, and hat its a t -HIV-1 act vity was not du  to cyto oxic 
effects on the host cells. Th se bioac ivity data als  pr vide v den  that  is  viable ad  
for developing new ligand  to i hibit HIV-1 inf c ion via CD4.  
Most of the comp unds collected fro  NCI database using the similar ty search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of eac  classifi ation and CD4 bindi g i ibition t 100 µM a  
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
 
     8.87 
Molecules 2018, 23, x 7 of 19 
 
 
Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependen  manner (D), and a CellTi er Blu assay  showed a omplet  lack of cy otoxicity 
effect (E). 
We also evalu ted t e anti-HIV-1 infecti n ctivity of 29 using the CEM-GFP r porter cell line. 
The GFP v lues w re ignifican ly lower for HIV-1 infe ed g oups treated with 29 than e group 
without drug treatme t, and  decr ase f the GFP values were dose-depend nt, indicating that 29 
w s an eff ive HIV-1 i hibitor identified by similarity search 3 s  le d emplate. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 showe  n  cy toxicity, as det mined by the cell viability 
in the CEM-GFP ll li e, whe  tes e at the h ghest con en r tion of 25 µ  (F gure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activit  was not due to cytot xic 
effects on the host cells. These bioa tivity data also provide vidence that 3 i  a viable lead compound 
for devel ping new ligands to i hib t HIV-1 infecti  via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substr ctures wit  3. These comp unds were classifi  into four classes for furth r 
studies. T e common s t res of ach classification and CD4 binding inhibit on at 100 µM e 
shown in Table 2. 
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Figur  3. The comp titiv  CD4 binding assay results of an logs of 3 (A). Am ng these analogs, 29 
showed the best binding affinity with an IC50 value of 14 µM (B,C). 29 i hibited HIV-1 infection in a 
dose-dep ndent manner (D), nd CellTit r Blue ssay of 29 show d a complete lack of cyt oxi ity
effect (E). 
We al o evaluat d th  n - IV-1 infect on activity of 29 using the CEM-GFP r porter cell lin . 
The GFP values  ignificantly l wer f r HIV-1 inf cted gr up  tr ated wi h 29 than the group 
wi hou drug treatm nt, and th  decr se of the GFP values wer  dose-d pendent, in icating that 29 
was a  ff ctive HIV-1 inh bi or den ifi by simil r y se rch using 3 as  lead templa e. Th  IC50 
valu  of 29 was 2 µM (Figur 3D), and 29 s owe  no cyt toxicity, s de ermine by he ce l vi bility 
in th  CEM-GFP c ll lin , h n t ted at the highest c ncentration of 25 µM (Figure 3E). These results 
confirme  tha 29 s a potent HIV-1 in ibitor, and h  it  ti-HIV-1 activity wa  no  du  to cyt tox c 
effects on the host cell . Thes bi a tivity ata also provid  evidence that 3  a viabl  l ad comp u d 
for d veloping new ligands o i hibit HIV-1 infection vi  CD4.  
M st f th  compounds collect d from NCI dat base using the similarity search appro ch share 
certain common substru tures with 3. These compou ds we e classified into four classes for further 
studies. The common structur s of eac  classific and CD4 bi ding i hibitio  a  100 µM are 
shown in Table 2. 
Table 2. The struc ures and inhibition data of compounds generated from t e NCI similarity search. 
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Figure 3. The comp titive CD4 binding assay re ults of l s of 3 (A). Among these analogs, 29 
showed the best binding affinity with  IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
ose-dep n ent ma ner (D), nd  CellTiter Blu  assay of 29 s wed a comple e lack of cytotoxicity 
ffect (E). 
W  al o valuated th  anti- I -1 in ct on ctivity of 29 using the CEM-GFP reporter cell lin . 
The GFP values wer  ign ficantly lo r for HIV-1 inf cted group treated wi h 29 than  group 
wi out drug tr tm nt, and th  cre  f th  GFP values wer  dose-d pe , indic ing that 29 
was n ffectiv  HIV-1 inhibi o  i e tif d by simil r y se r h u ing 3 s  lead templa . Th  IC50 
valu of 29 was 2 µM (Figur  3D), nd 29 sh wed no y otoxicity, as d erm n d y e ce l vi b lity 
in h  CEM-GFP ce l li , hen t sted at the high st conc ntration of 25 µM (F gure 3E). These results 
con irmed that 29 is  po ent HIV-1 inhibitor, and th t i  a ti-HIV-1 activity was n  du  t  totoxic 
ffects n he host cell . Thes  bioactivity data al o provid  v denc  th t 3 i   viable l ad c mpound 
f r velopi  new liga ds o nhibit HIV-1 infection vi  .  
Most of the c mp nds collected fro  NCI database using t e similarity sea ch approach share 
certa  common substr ctures with 3. Th se compounds were classifi d into four classes fo  further 
studies. The commo struc ur s f e c  classifica and CD4 bi ding i h bition a 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding ass y results of analogs of 3 (A). Among these analogs, 29 
sho ed the best binding affinity wit  an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-d p nd nt man er (D), a   CellTit r Blu  assay of 29 s owed a c mplete ack of cytotoxicity 
fect (E).
We l o evaluated the nti-HIV-1 nfecti n activi y of 29 u ing the EM-GFP r p rter cell line. 
Th  GFP values w r  sig ifican ly lo er fo  HIV-1 inf cted group  trea ed wi h 29 than the group 
ithout d ug reatment, and th  ecrease of he GFP values were dos - epe dent, indicating that 29 
was an effective HIV-1 i hibit r i entifi d by s milarity s arch using 3 s a lead templ te. The IC50 
value f 29 as 2 µM (Fig re 3D), a 29 sh wed no cytot xicity, as det rmine  y he cell viability 
in t e CEM-GFP c ll lin , wh n tested at th  highes  concentr tion of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 i hibitor, and that its an i-HIV-1 activity was not due to cytotoxic 
effe ts on t  host cells. These bioactivity data also pr vide evidence that 3 is a viable lead compound 
f r ev l ping new li ands t i hib t HIV-1 infectio  via CD4. 
Most of the compounds collected from NCI database us ng the similarity search approach share 
certain common substructures with 3. These compounds were classified into fo  classes for further 
tu ies. The comm n struc ures of each classificati  a d CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The struc ures nd inhibiti n data of compounds generated from the NCI similarity search. 
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Figure 3. The competitive CD4 bi ding assay results f analogs of 3 (A). Among these analogs, 29 
showed the best bi ding affinity with n IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infectio  in a 
dos -depend nt ma r (D), an a C llTit r Blu assay of 29 sh w d a c mpl te ck of cytotoxicity 
ffect (E). 
W  also evalu ted the anti-HIV-1 infecti  activity of 29 u i g th  CEM-GFP reporter cell line. 
Th  GFP alu s were signifi a tly lo e  for HIV-1 i fec ed groups treated with 29 than the group 
withou  drug tr tment, and the decrease of the GFP values were dose-depe en , indic ing that 29 
was an effectiv  IV-1 i hibi r i ntif d by simil rity search u ing 3 s  lead tem late. T e IC50 
value f 29 wa  2 µM (Fig  3D), and 29 h wed no ytotoxicity, as d termin d by the cell viability 
in the CEM-GFP cell li e, when tested  the high st c ce tration of 25 µM (Figure 3E). These results 
c nfirmed that 29 is a poten  HIV-1 hibitor, and th t its anti-HIV-1 a tivity was n t due to ytotoxic 
effect  n the host cells. Th s  bioact vity data also provide vid nce that 3 is a viable lead compound 
f r evelopin  w lig s to inh bit HIV-1 infe tion via CD4.  
Most of the c p un s collected from NCI database using the similarity sea ch approach share 
certain common sub tructures with 3. These compounds were cla sified into four classes fo  further 
studies. The mo  tru r s of eac  classificati  and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding as ay results of analo s o  3 (A). Amo g thes  an logs, 29 
showed the best bi ding affinity with an IC50 value of 14 µM (B,C). 29 inhibit d HIV-1 infectio  in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluated the anti-HIV-1 infection activi y of  s ng he CEM-GFP r porter cell li . 
The GFP values were significantly lower for HIV-1 infected groups tr a d wit  29 than the group 
without drug treatment, and the decr e of th  GFP valu s were d se-depende t, indic ting th t 29 
was an effective HIV-1 inhibitor identifi d by similarity search using 3 as a le d template. The IC50 
value of 29 was 2 µM (Figure 3D), a d 29 showed no ytotoxicity, as d ermin d by the ell viability 
in the CEM-GFP cell line, when ested at the highe concentration of 25 µM (F gure 3E). These results 
confirmed that 29 is a pote t HIV-1 inhi i or, and t at its ant -HIV-1 ctivity was not ue t  cy ot xic 
effects on the host cells. These bioactivity data also provid  vi ence t  3 is  vi ble le d compou d
for developing new ligands t  inhi it HIV-1 infec ion via CD4.  
Most of the compounds collected from NCI database using the si ilarity earch a proach share 
certain common substructures with 3. Th e comp unds were las if ed into four classes for further 
studies. The common tructures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. T e competit v CD4 bind g assay results of analogs of 3 (A). Am g th se analogs, 29
sho d th  best binding affinity wit  an IC50 v of 14 µM ( ,C). 29 i hibited HIV-1 infecti n in  
dose-dependent manner (D), and a CellTiter Blue assay of 29 showed a co plete lack of cytotoxicity 
effect (E). 
We also evaluated the n -HIV-1 nfecti  activit   29 using th  CEM-GFP repor r cell line.
The GFP val es e significa tly low r f r HIV-1 infect d groups tr at d w th 29 than h  group 
without drug reatme t, a d h  decrease f the GFP value  were dose-dependent, in ic ting tha 29 
was an e fective HIV-1 inh bit r dentif ed by simil rit  search using 3 as a lead templ te. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 s owe  no ytotox ci y, as det rmined by the cell viability 
in the CEM-GFP cell lin , w en teste  at he highest concentration of 25 µM (Fi ure 3E). These results 
con irmed that 29 s a potent HIV-1 inhibitor, and a  its an i-HIV-1 act vity w s not due to cyt t xic 
effects on the host cells. These bi activity ata also pr vide evid nce that 3 is a viable lead compound 
for developing n w liga ds to i hibit HIV-1 infection vi  CD4. 
Most of th  compounds collect d from NCI dat base using the similarity search approach share 
certain common s bstru ures with 3. These compou ds we e class fie  into four classes for further
studie . The commo  structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 bind  assay results of l s of 3 A). Amo g these a logs, 29 
showed he best bi ing affi ity with  IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infectio  in a 
ose-dependent nner (D), and a CellTiter Blu  assay of 29 sh wed a complete lack of cytotoxicity 
effect (E). 
We lso val ted the anti-HIV-1 inf cti  a ivity f 29 using th CEM-GFP reporter cell line. 
The F  valu s wer  signifi antly low r fo HIV-1 infecte groups treat d with 29 than he group 
wit out drug tr ment, an t e d crea  of th  GFP values were dose-depe den , indic ing th  29 
was an effective HIV-1 inhibi o  i entif  by similarity se r  u ing 3 s a le  t l te. The IC50 
value of 29 as 2 µM (Figure 3D), and 29 sh wed no y t xicity, as d termin d by the c ll viability 
in the CEM-GFP cell li e, whe  tested at the igh st concentrat on of 25 µM (Fig re 3E). These results 
confir d hat 29 is a po ent HIV-1 inhibit r, an  that i  ti-HIV-1 acti ty w s n t d e to ytotoxic 
ffects n he host c lls. These bioactivity data lso provide vidence t at 3 is a viable lead c mpound 
f r developin  new liga ds o inhibit HIV-1 infection via CD4.  
M st of the comp unds collected fro  NCI database u i g t e simi rity sea ch app oach share
certain co on ubs r ctures with 3. Th se c mpounds were classifi d int  four classes fo further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
hown in Table 2. 
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Fig r  3. The competitive CD4 bindi g assay results of analo s of 3 (A). Amon  these an logs, 29 
ho d the best bi ding affinity wi  an IC50 value of 14 µM (B,C). 29 inhibit d HIV-1 infe tio  in a 
dos -dep ndent man  (D), a d a Cel Tit r Blu assay of 29 s owed  c mplete ck of cytotoxicity 
fect (E). 
We also eval ted the anti-HIV-1 inf ction activity of 29 using t  CEM-GFP reporter cell line. 
The  values wer  significantly l er f r HIV-1 i fect d groups treat d with 29 than the group 
wit out drug treatme t, and t e decrease of the GFP values ere dose-dependent, indicating that 29 
was an effective HIV-1 inhibitor identified by similarity search using 3 s a le  te late. The IC50 
alue of 29 was 2 µM (Figure 3D), and 29 showe  no cytotoxicity, as determine  by the cell viability 
in the CEM-GFP cell line, whe  tested at the highest conce tratio  of 25 µM (Figure 3E). These results 
confir ed that 29 is a potent HIV-1 inhibit r, and that its ti-HIV-1 ctivity was n t d e to cytotoxic 
effects on the host cells. These ioactivity data also provide evi ence t at 3 is a viable lead compound 
for dev loping ew ligands t  i hibit HIV-1 infectio  via CD4.  
Most of the compounds collected from NCI database using the similarity searc  approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
stu ies. The common struc ures of each classificati n and CD4 b nding inh bition at 100 µM are 
shown in Table 2. 
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Figure 3. The c m etitive CD4 binding assay r sul s of anal s of 3 (A). Amon  hese an logs, 29 
showed the b st bi di g f inity with an IC50 value of 14 µM (B,C). 29 i hibited HIV-1 nfectio  in a 
dose- ependen mann r (D), and a CellTi er Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
e also eval ated t an i-HIV-1 infect on ac ivity of 29 using t CEM-GFP repo ter cell line. 
Th  F va u s w r si nificantly lo r for HIV-1 inf c  grou s tr t d with 29 than the group 
w t ou  drug tr atment, and t e cre s of th GFP v l es were d se-d p nden , indicating that 29 
was an effect ve HIV-1 inhi it r n fied by simil r ty se rch using 3 s a le  te late. The IC50 
valu of 29 was 2 µM (Figur 3D), and 29 h wed no c ot xicity, as d t rmined by th  ce l viability 
in  CEM-GFP cell line, when te ted at t e highest concentr tion f 25 µM (Figure 3E). These results 
co firmed th t 29 is poten  HIV-1 i hibitor, an  tha  i n i-HIV-1 activity was not d e to cytotoxic 
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for dev loping ew l gands to inhibit HIV-1 infection via CD4.  
Most of the ompounds coll ct d from NCI atabase using the similarity arch approach share 
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shown in Table 2. 
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Amo g these analogs, 29 
showed the best binding ffinity with n IC50 v lue of 14 µM (B,C). 29 inhibit d HIV-1 infection in  
dose-dependent manner (D), nd a CellTite Blue say of 29 showed a complete lack of ytotoxici y 
effect (E).
We also evaluated t e anti-HIV-1 infectio  activi  f 29 us ng  CEM-GFP report r c ll l e.
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding ffinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-depende t manner (D), and a CellTit Blu  ssay of  showed a complete lack of cytotoxicity 
effect (E).
We also l ated e nti- IV-1 inf c o  cti it  f 29 u ing e CEM-GFP r po er c ll li e.
Th  GFP values ere significantly l wer f r HIV-1 infecte  groups tr ed with 29 han t e g oup 
without drug treat nt, a d th  d cre se f th  GFP v l s were dose-d pe d , n icating t t 29
w s a  effec v HIV-1 i hibitor identifi d by sim l rity a h u g 3 as a l d templa e. The IC50
valu  o  29 wa  2 µM (Fig re 3D), and 29 showed no yto oxic ty, s etermined by the ll viab lity
in the CEM-GFP ce l li , h  te te  at the highes  concen ration of 25 µM (F gure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibi or, and hat its anti-HIV-1 ac ivit  was not due to cytot xic 
effects n the h st c lls. These b oactivity d a als  r v de v d nce th t 3 s a v able l ad compou d 
for developing ne  lig n s to i hibit HIV-1 infe  via CD4.  
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Figure 3. T e competit v CD4 bind ng assay results of analogs of 3 (A). Among these analogs, 29
show d th  best binding ffinity with an IC50 v e of 14 µM ( ,C). 29 i hibited HIV-1 infecti n in  
dose-dependent manner (D), a d a CellTite Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E).
We als  evaluated t  n -HIV-1 nfectio  ac vit  29 using the CEM-GFP repor r c ll line. 
The GFP val s e significantly low r f r  d groups tr at d with 29 than he group 
without drug r a me t, a  t  d reas  f t e GFP va ue  we ose-depend nt, in ic ting that 29 
was an fective HIV-1 inh bitor entif by simil rity se ch u ing 3 a l ad t mpl te. Th IC50
value of 29 w s 2 µM (Figur 3D), a d 29 s ow  o yto x ci y, as det rmin d by t e cell viability 
in the CEM-GFP cell lin , w en tes e  at he igh t conc ntrat on f 25 µM (Figure 3E). Th se results 
con irmed that 29 s a potent HIV-1 in ibitor, and ha  its n i-HIV-1 ctivity w s not due to cytot xic 
effe ts on the host cells. Thes bi activity ata also pr vide ev d nc  th t 3 is  viable le d c mpound 
for d veloping n w ligands to i hibi  HIV-1 infection vi  CD4.  
Most of th  compound  collect d from NCI dat base sing the similarity search approach shar  
ertain common bs ru ur s with 3. T ese compou d  we e class fie  in o four cl sses fo  further 
studies. The commo  structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 bindi g assay results of l s of 3 (A). Amo g these a alogs, 29 
showed the best bi ing ffi ity with  IC50 v lue of 14 µ  ( ,C). 29 inhibited HIV-1 infection in a 
o e-d pende t m ner (D), and a CellTite Blu  assay f 29 sh wed a complete l ck of cytotoxicity 
effect (E).
We also v l ted t e anti-HIV-1 nf ctio  cti i   29 u ing e CEM-GFP repor r cell li .
The valu s w r  sig f antly lower fo  HIV-1 infecte groups tre t d with 29 than he group 
wit ou  drug tr t e t, a t e d crea  f th  GFP v lues were dose-d pe d n , in ic ing th  29
was effective HIV-1 i hibi o identif d by similarity s h u ing 3 s a le  t l te. The IC50
value of 29 was 2 µM (Fig re 3 ), and 29 s wed no y tox c ty, as t rmin d by the c ll viability
in the CEM-GFP c ll li , w e teste  at he ig st co centration of 25 µM (Fig re 3E). These results 
confi m d at 29 is a po ent HIV-1 i hibit , and that it  i-HIV-1 acti ty w s n t d e to ytotoxic 
ffect  n he host c lls. The  bioactivity ta also r vide vid nce t at 3 is a vi ble lead compound 
f r developin  new liga ds o inhibit HIV-1 infection via CD4.  
M st of the comp unds collected fro  NCI database u i g t e si i rity sea ch app oach s are 
certa n c on bs r ctures with 3. Th se c mpounds wer  class fi d nt  four cl sses fo  further 
studies. The commo  structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding ass y results of analogs of 3 (A). Among these analogs, 29 
showed the best binding ffinity with an IC50 value of 14 µM (B,C). 29 inhibi d HIV-1 infection in a 
dose-d p ndent man (D), an  CellTite Blue assay of 29 s owed a c mple e ack of cytotoxicity 
fect (E).
We also evalu ted t e a ti-HIV-1 nf ction a ti i  f 29 using e CEM-GFP r porter cell li e.
Th FP values were significa tly l er f r I -  i fected groups treated with 29 than the group 
without drug treat e t, a d the ecre  f the GFP v lues ere dose-de e d nt, in ic ting that 29
was a  effective HIV-1 in ibit r identified by similarity sea ch u ing 3  a lead plate. The IC50
alue f 29 was 2 µM (Fig re 3D), d 29 sh we  no cyt t xic ty, as et rmine y e cell viability
in the CEM-GFP c ll line, he  teste  at th  highest conce tration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its an i-HIV-1 activity was n t due to cytotoxic 
effe ts on t  host cells. These bi activity ta also r vide vidence that 3 i   viable lead compound 
for developing new ligands to i hibit HIV-1 infectio  via CD4.  
Most f the compounds collected from NCI database us ng the similarity search approach share 
c rtain common ubs ructures with 3. These compounds w re classified into fo  cl sses fo  further 
stu ies. The comm n struc ures of eac classificati  a d CD4 b ding inh bition at 100 µM are 
shown in Table 2. 
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Figure 3. The comp itiv  CD4 binding assay results f analogs of 3 (A). Among th s  analogs, 29 
showed the best binding ffinity with an IC50 value f 14 µM (B,C). 29 inh bited HIV-1 inf ction in a 
dos -dependent manner D), and  C llTit r Bl e as ay of 29 showe  a complete lack of cy tox city 
effect (E). 
We als  evalu e  the anti-HIV-1 infect  a tivi  of 29 using the CEM-GFP r porter cell line. 
Th  GFP values were s nificant y lower f r HIV-1 i f t d gr ups treated wit  9 than the group 
without drug treatment, and the ecrease of the GFP values w re e-dependent, ind cati  t t 29 
was an ffective HIV-1 inhibitor ide tified simil rity se rch us ng 3 as  lead empl te. The IC50 
value f 29 was 2 µM (Figure 3D), and 29 sh w d o cy tox ci y, s etermined by the cell via ility 
in the CEM-GFP c ll line, w n te ted at he h ghest conce tration of 25 µM (Figure 3E). T es  results 
confirmed that 29 s a potent HIV-1 inhibitor, and that ts anti-HIV-1 activity w  not ue t  cytot xic 
effect  on the host cells. h e bioact vity dat al o pr v de evide c  th 3 is  viable lead c pound 
for developing new l gands to inhibit HIV-1 nfection via CD4.  
Most of the compounds llected from NCI database using the similarity search approach share 
certain common su str ctures with 3. These comp unds were class fi i to four cla s s for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. The compet tiv  CD4 bindi g assay r lt  of anal gs of 3 (A). Am g these a logs, 29 
sho ed the bes  i g affi ty with  IC50 valu  of 14 µM (B,C). 29 inhibi d HIV-1 infection in  
d s -d p nde t m n r ( ),  a C llTiter Blue ssay f 29 showe a o p e l k of ytotoxicity
ffect (E).
W  als  eval ted t e anti-HIV-1 infecti n activit  f 29 us ng  CEM-GFP report r cell li e. 
The  values were sig ifica tly low r fo  HIV-1 infected group  treat d with 29 than th  group 
wit out drug t t, d t e dec ease f the GFP values were dose- ependen , in ic ting h  29 
was  effective HIV-1 inhibitor i entifi d by similarity s r  using 3 s a le  t late. T e IC50
value f 29 was 2 µM (Fig  3 ), nd 29 how d no cytotoxic ty, as etermined by the c ll vi bility 
in the CEM-GFP ell line, w n t st  at the high t c c ntration of 25 µM (Figure 3E). These results
onf rm d a 29 is a potent HIV-1 inhib or, and that it  nt -HIV-1 activ ty w s not d  to cytotoxic
eff cts on h  host cell . These bio t vi y a als  r vide vi enc  t  3 is  viable lead ompound 
for dev loping new ligands to inh bit HIV-1 infection via CD4.  
Most of the compounds collected from NCI database usi g the simi rity search app oach share 
certa n c mmon ubs ructures with 3. The e compounds wer  classified nto four cl sses fo  further 
studies. The ommon structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figur  3. The competitiv CD4 binding a say esult  of analogs of 3 (A). Among t ese an logs, 29 
showed the b s  d ng affi i y w h an IC50 v l  of 14 µM (B,C). 29 inhibi d HIV-1 infection in a 
os -d p dent man (D), and a CellTite  Blu  s ay of 29 s ow d a c mp e a k f cytotoxicity 
f c  (E). 
We lso evaluate  the a ti-HIV-1 i fection activit  f 29 using th  CEM-GFP report r cell line. 
The FP values were significantly lo er for HIV-1 infected gro ps treated with 29 than th  group 
with ut drug r atme t, a  the decrease f t e GFP values ere dose-dependent, i icating ha  29 
was an ive HIV-1 inhibitor identifie  by similarity search using 3 s a lead t pl te. The IC50
al e of 29 was 2 µM (Figur  3D), nd 29 show   cy t xicity, as de rmine by the cell viability 
i  the CEM-GFP ell line, whe  t ste  t the highest conc ntration of 25 µM (Figure 3E). These results
onfirmed hat 29 is a potent HIV-1 inhib or, and that its anti-HIV-1 activ ty was n t du  to cytotoxic
effects on the host c lls. These bioactivi y data lso prov de evidence that 3 is a viable lead c mpound 
for developing new ligands to i hibit HIV-1 infectio  via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
c rtain common ubs ruc ures with 3. T ese compounds w re classified into four cl sses fo  further 
stu ies. The common struc ures of each classificati n and CD4 b nding inh bition at 100 µM are 
shown in Table 2. 
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F gure 3. The comp titive CD4 binding assay results of a al s of 3 (A). Among these an logs, 29 
sh we  the b st n g ff n t  with a  IC50 val  of 14 µM (B,C). 29 inhibi d HIV-1 infection in a 
se-d pendent manner (D), and a CellTiter Blu  s ay of 29 s ow d a comple la k of cytotoxicity 
ffect (E). 
We also evaluate  t  anti-HIV-1 i f ct on activi  of 29 using t  CEM-GFP repo ter cell li e. 
Th  GFP values w re s gnificantly low  fo IV-1 inf c grou  t ted with 29 than the group 
ithou  drug tr a ment, and e ecre se of h  GFP v l es ere dose-dep nden , ndicating that 29 
w s a  eff ct ve HIV-1 inhi it r id ntifi d by imilarity se rch using 3 s a lead template. The IC50 
value of 29 was 2 µM (Fig re 3D), and 29 howed no cy ot xicity, as termined by th  ce l viability 
i he CEM-GFP cell line, when tested at h ghest conce tration f 25 µM (Figure 3E). These results 
confirmed that 29 i   poten  HIV-1 inhibi or, an  that i s a i-HIV-1 ctivity was not due to cytotoxic 
effects on he o t ell . T es  b ct vity d ta also vide vidence th t 3 is  viable lead compound 
for dev loping ew l g nds t  inhibit HIV-1 infecti n via CD4.  
Most of the ompounds collec d from NCI database using the similarity arch approach share 
certain co mon s bst ctures with 3. Thes  c mpound  were classified into our classes for further 
studies. The ommon structures of each classificati  and CD4 bi ding inhibition at 100 µM are 
shown in Table 2. 
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Figur  3. The omp titive CD4 binding ass y resul s of al gs of 3 (A). Am g th se n logs, 29 
show d t  best binding affini y ith an IC50 v lue 14 µM (B,C). 29 inh bit d HIV-1 infectio  i  a 
dose-dependen  ann r (D), and a C l Titer Blue as y o  29 showed a c mplete lack of cytotoxicity 
effect (E). 
We a o evaluated he anti-HIV-1 infection activ ty of 29 u ing the CEM-GFP r porter ce l l e. 
The GFP valu s ere sig ificantly lower for HIV-1 infecte  group  treate  with 29 than the gro p 
without drug treat ent, a d the decre se of the GFP valu  were ose-dependent, i d cating that 29 
was an eff c ive HIV-1 i hibito  i entified by im larity searc  u ing 3 a  a lead template. The IC50 
value of 29 was 2 µM (Figur  3D), a d 29 howed  cyt toxicity, as determine  by the cell viabil y 
in the CEM-GFP cell lin , when t sted at the ig est c ncentratio  f 25 µM (Figure 3E). These resu ts 
confirmed that 29 is a potent HIV-1 inhibit r, a d t at its nti-HIV-1 acti ity w s not due to cytotoxic 
effects on the host cells. Th se bioactivity data also provide evidenc  t at 3 is  viable lead compound 
for developing new ligand to inhibit HIV-1 nf ction via CD4. 
Most of t e co pou ds collecte  from NCI datab se usi g the similarity search approach share 
certain common substructures wit  3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM ar  
shown in Table 2. 
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F g re 3. Th comp titive C 4 bindi g a s y res lt  of analo s f 3 (A). A o g th se an log , 29
sho ed the best b ding af i ity wi an IC50 valu of 14 µM (B,C). 29 ibi d HIV-1 inf ti in a 
d s -depe den  m n r (D),  a CellTit r Blu s y of 29 owed  complete l ck of ytotoxici y
ct (E .
We als  evalu te  t  anti- I -1 fect on c ivity f 29 using e CEM-GFP report r cell lin . 
The GFP values were significantly lower for  ed groups treate  with 29 t an the group 
without dr g reat nt, nd th  decr as  of the GFP v lue  wer  dos -d pend nt, indic ting that 29 
was an ffective HIV-1 hib or i ent fi d by si ilarity sea ch u ing 3  a l ad template. Th IC50 
value of 29 was 2 µM (Fig re 3D), and  showed o c totox city, as etermin d b e cell viability 
in the EM-GFP cell lin , h n t ste  at he highest c centrati  of 25 µM (Figure 3E). T ese r sults 
confirmed that 29 is a p te t HIV-1 i i it r, d hat its anti- I -  ctivi y was not due to c totoxic
eff cts on the h st c lls. These bio ctivity dat  lso provid vidence th t 3 is a viable l ad com ound 
for dev lop ng new ligands to inhibit HIV-1 in ection via CD4.  
Most of the c mp nds collected fro  NCI dat bas  using the similarity se rch app ach share 
certai common substructures with 3. These compounds were classified into four classes for further 
studies. The common structur s of each classifica  and CD4 bind ng i hibition at 100 µM are 
shown in Table 2. 
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Figur 3. The co petitive C 4 bi i g assay results of an lo s of 3 (A). A g hese n l gs, 29
show d the best b ding affini y wi n IC50 valu of 14 µM (B,C). 29 i hibit d HIV-1 infe tio  in a 
dos -dependent a n r (D), an  CellTiter Blue ss y of 29 sh wed  c mple e l ck of ytot xicity 
eff ct (E). 
We al o ev luat d t e a ti- IV-1 infection acti ty of 29 using e CEM-GFP reporter cell li e. 
The GFP values re ign f cantly lo r f r HIV-1 inf cted gro ps trea ed wi  29 than the group 
without drug treat ent, and th  decrea  of th GFP v lu s wer ose-depe n , indic ing that 29 
as a  effec ive HIV-1 i hibi o  i ntif d by similarity s ch u ing 3 as a l ad template. Th  IC50 
value f 29 as 2 µM (Fig re 3D), a d 29 sh wed no yt toxicity, as termin d by the ce l vi bility 
in the CEM-GFP c ll li e, h  test d  th high st c centr ti  f 25 µM (Fig re 3E). T ese res lts 
c fir d t at 29 s a pote t HIV-1 i hibit r, and tha  its a ti-HIV-1 activity was n  due to ytotoxic 
effects n the st cells. These bioacti ty data also provide vidence th t 3 i  a vi ble lead compound
f r dev lopin  ne liga ds t  i hi it HIV-1 infecti  vi CD4. 
Most f th  omp unds c llected from NCI d ta ase using the similarity se ch approach sh re 
certai  common substructures with 3. These compounds were classifi d into four classes fo  further 
studies. The common structures of eac  classificatio and CD4 bi ding i hibition at 100 µM are 
s own in Table 2. 
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Figure 3. The c peti ive CD4 bind g assay resul s f a a o s of 3 (A). Among th e an l gs, 29
sho  the b st bi ing affini y wi  an IC 0 al  of 14 µM (B,C).  i hibit d HIV-1 infe tio  in a 
dos -dependent manner (D),  a C llTit r Blu  ass y of 29 howed a compl te l ck of cytotoxicity 
eff ct (E).
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Figure 3. The c m titive CD4 bindi g assay r ults of analogs of 3 (A). A ong h  n logs, 29 
showed the best bin ing affinity ith a  IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infecti  in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 s ow d  compl te l k of ytotoxicity 
effect (E). 
We als evalua ed  anti-HIV-1 nfect o act v y of 29 usi g t e CEM-GFP report r cell l ne. 
The GFP val es w re signi ic ly low r for HIV-1 inf te  g up  t t d with 29 h n the roup
without drug treatment, and the d cr ase f the GFP val e  w e d s -d pend nt, i di ating t t 29 
was an effective HIV-1 in ibitor identifi d by si ilarity s rch using 3 as a lead template. The IC50 
va ue of 29 was 2 µM (Figure 3D), a  29 show d o cytotoxicity, as determined by the cell viability 
in the CEM-GFP cel  line, when test d at the highest concentrati  of 25 µM (Figure 3E). Th  result  
confirmed that 29 i  a pot nt HIV-1 inhibitor, a d th t its anti-HIV-1 activity was not d e to cytotoxic 
effects on the host cells. These bi activity data also provide evi ence that 3 is a viable lead compound 
for developing new ligands to inhibit HIV-1 infection via CD4.  
Most of the compounds collected fro  CI databas  using t e similarity search approach share 
certain common substructures with 3. he e compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µ  are 
shown in Table 2. 
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Figure 3. The comp titive CD4 bindi g a say esults  an log  f 3 (A). Amo g th se analogs, 29
sho ed the best bindin  affinity ith an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 inf ction  a 
dose-depe dent m er (D), and a CellTiter Blue a say of 29 showed a complete lack of cyto xicity 
effect (E). 
W als  evaluated the ant -HIV-1 infect on a tivity of 29 usi g the CEM-GFP report  cell line.
Th  GFP values were signific tly lower for H V-1 infect d gr up  treated with 29 than e group
wi ho t d ug tr at nt, and th  decr ase of th  GFP value  were dos - epen ent, i i ting th t 29
was an eff ct ve HIV-1 nhi r id t fied by imi rity s arch using 3 as a lead template. The IC50
value of 29 as µM (Figure 3D), nd 29 showed no c totoxicity, as det rm ed by the cell vi bility 
in the CEM-GFP cell line, when test d at t  highest c centr ti n of 25 µM (Figure 3E). T se esults 
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W ls  valuat d th  a ti-HIV-1 i fection activity of 29 using th CEM-GFP r porte  ell line.
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without d ug tre tm nt, an  th  decre se of the GFP valu s were dos - p nd nt, i dicating that 29
was a  effecti e HIV-1 inhibitor ide tifi d by si ilarity search using 3 a  a le d templat . Th  IC50 
valu  f 29 was 2 µM (Figur  D), nd 29 s we  o ytotoxi ity, as d termined by t e cell vi bility 
i  t e CEM-GFP ell line, wh  t st d at t  ighest c ntr tio  of 25 µM (Fig re 3E). T se res lts 
c firm d at 29 i  a otent HIV-1 inhibitor, a d hat its nti-HIV-1 activity w s n t due to cytotoxic 
effects  the ost cells. The e bi activity ata al o provide evidence th t 3 i  a vi ble lead compound 
f  developing n w ligands t  inhi it HIV-1 i fecti n via CD4.  
Most of the compound  llecte  from NCI d tabase using the similarity se ch approach sh  
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Figure 3. The comp t tiv D4 bi i g assay result of nalogs f 3 (A). Among th se analogs, 29 
s owed the best binding aff ity with  C50 valu  of 14 µM (B,C). 29 inhibited HIV-1 infect on in a 
do e-d pe de t m nner (D), and a CellTiter Blue ss y f 29 sh wed a com lete l ck of cytotoxici y 
ffect (E).
W lso ev lu t d th anti-HIV-1 inf t on ctivity of 29 usi  t e CEM-GFP r porte  cell line. 
T  GFP valu s w  signific tly lower f r I -  infected groups tr ted with 29 t an the group 
wit out dr g tr tm nt, nd th  ecre se of h  GFP values wer  dos - ep n n , indic ing that 29 
as a  effectiv  HIV-1 inhibi or i e tif d by si ilarity earch u ing 3 as a lead te plate. The IC50 
val e f 29 w s 2 µM (Figu e 3D), nd 29 s w  o yt toxi ity, as ter n d b t e cell viability 
i  t e CEM-GFP ell li , whe  t sted t the high t c t tion of 25 µM (Fig re 3E). T ese results 
c nfirmed that 29 i  a po ent HIV-1 i hibitor, a d that its anti-HIV-1 activity w s n t due to ytotoxic 
effe ts  the h t ells. These bi activity ata al o provide vid nce that 3 is a viable lead com ound 
f  developin  new liga d  to inhibit HIV-1 i fection via CD4.  
Most of th  omp unds collected from NCI dat base using the si ilarity sea ch appr ch share 
ce t in common ubstruc ures with 3. T es  compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
how  in Table 2. 
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showed th  b st binding affini y ith an IC50 valu  of 14 µM (B,C). 29 in i ited HIV-1 infection in a 
dose-depende t manner (D), and a CellTiter Blue assay f 29 showe  a c mplete lack of cytotoxicity 
eff ct (E). 
We also valuat d t e an i-HIV-1 inf ction ctivi y of 29 usi g the EM-GFP r porte ell line.
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valu  of 29 was 2 µM (F gure 3D), a d 29 showed n  ytotoxicity, s d ter i d by the cell vi bili y
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c nfirmed that 29 is a potent HIV-1 inhibitor, and hat ts anti-HIV-1 activity was not due to cytotoxic 
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Figur  3. Th  compet tiv  CD4 bindi g assay resul s of a alogs of 3 (A). Amo  t ese analog , 29 
sho d the best bi ding f i ity wi h a  IC50 v lue of 14 µM (B, ). 29 inhibited HIV-1 infec i n in a 
ose-d pendent man e  (D), a d a llTit Blu  ssay of 29 showed a co plet  la k of ytotoxicity 
effe t (E).
We ls  evaluated e a ti-HIV-1 f tio tivit f 29 usi g e CEM-GFP repor r c ll li .
e GFP valu s w re significantly lowe  for  d groups treat d with 29 t an the group 
without dr g reat , nd the ecreas  of t e GFP v lues wer do e-depen nt, in c ting that 29 
was a  ff ctiv  HIV-1 ib t  tifi d by si il rity a ch u i g 3  a l a mplat . T  IC50 
value of 29 w s 2 µM (Fig r 3D), a d show  o cytotox c ty, as etermin d b  t e cell viability 
in the CEM-GFP cell lin , when t st at t  highest conc n tion of 25 µM (F gure 3E). T se results 
confirmed that 29 is a potent HIV-1 i h bitor, and that its anti- act vity was not du  to cytotoxic 
effects on the h cells. These bioactivity data so pr vide vidence th t 3 i   v ble lead c m ound
for developing n w ligands to i hi it HIV-1 inf c ion via CD4.  
M st of the comp unds llected fro  NCI dat ba e using the similarity se rch appr ach share
certain common ubs ruc ures with 3. T ese compounds were cl ssified int  four cl sses fo  further 
studies. The common structures of each classification and CD4 binding inhibition at 10  µ  are 
shown in Table 2.
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Figure 3. Th  co pe i iv  CD4 bi di  assay r su ts of a alo  of 3 (A). Amon  t ese an l g , 29
sho ed the b st b nding ffin ty wit n I 50 valu  of 14 µ  (B,C). 29 inhibit d HIV-1 inf tio  in a 
do -d pende t m er (D), an a CellTite Bl e as ay f 29 sh we a ompl te l ck of cyto oxicity
eff ct (E).
We als v l a ed e -HIV-1 f tio ct t of 29 using CEM-GFP reporte  cell li e.
T e  valu s w re sign f cantly low r f r I -1 infect d gro ps reat d with 29 than t e group
wit out drug treat t, and the decr a e of the GFP v lu s were dose-d pe d n , in ic ing that 29
was a  ffectiv HIV-1 i b  ntif ed by si ilarit  s a ch u ing 3 s a le t plat . T  IC50
value f 29 as 2 µM (Fig re 3D), a d 29 sh w d no yto oxicity, as termin d b  the cell vi bility
in the CEM-GFP c ll li e, wh n t st at t hig st c nc nt tio  of 25 µM (F ure 3E). These r s lts
confirmed that 29 is a potent HIV-1 i h bitor, and at its nti-HIV-1 act vity was n t d  to yt toxic 
effects n the cells. These bioactiv ty a a a so pr vide videnc  t  3 i  a v ble lead com ound
f  developin n w liga ds to inhi it HIV-1 inf c i n via CD4.  
Most of the comp unds llected from NCI d base using the similar ty sea ch appr ach sh
certai common ubs ructures wi h 3. Th s  compounds were classifie  nto four cl sses fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 10  µ  are 
shown in Table 2. 
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Figur  3.  co pe iti e D4 bindi  ass y resul  of anal gs of 3 (A). Among t se anal g , 29
sh d he b t bindi g affi ity wit  n IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
e- epende t m ner (D), a  a CellTiter Blu assay f 29 sh wed a com let  l ck of cytotoxicity 
ff ct (E). 
We ls  eval t  a t -HIV-1 nf ti  a t ty f 29 using t e CEM-GFP reporte  cell line.
Th   values w re signif cantly low r f r HIV-1 inf c  gro ps tre ted with 29 t an t e group
witho d g tr t ent, a d t e ecre of t  GFP v lue  ere dose- pe d n , indi ng that 29
was n f ct v HIV-1 in  i ntif d by similarity rc  u ing 3 s  l  t lat . Th  IC50
v lue f 29 s 2 µM (Figure 3D), nd 29 s wed o y otoxi ty, as d termin d b  the cell viability
in t e CEM-GFP cell li e, wh n tested t the high st c ncent atio  of 25 µM (Figure 3E). These res lts
c nfirmed that 29 i a potent HIV-1 inh bitor, and hat i s ti-HIV-1 ctivity was n t d e to ytotoxic 
effects n the s ells. The e bi act vity ta l o rovide vidence t t 3 is a v ble lead c m ound
f r dev lopin new liga ds t inhibit HIV-1 i fecti  via CD4.  
Most of the comp unds collected from NCI d base using the similar ty sea ch appr ach sh
cert i commo  ubstruc ures with 3. T es  compou ds were classified to our cl sses fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compounds generated from th  NCI simil rity search. 
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Figur  3. The c p titiv D4 binding ass y result of anal s of 3 (A). A on  these an l gs, 29
s ow d the est di g f i ty with n IC50 valu  f 14 µM (B,C). 29 i hibi d HIV-1 infe tio  in a 
os - ependen  ann r (D), an a CellTite Blu assay of 29 sh w d a comple  l k of cytotoxicity 
ff ct (E).
W  so valu d  an i-HIV-1 inf ction a t vit f 29 using t e CEM-GFP reporter cell line.
Th  GFP a ues were sign fic ntly ow r for HIV-1 i f c gro ps tre ted with 29 t an the group
withou drug tr tm n , a d t  cr f th  GFP v lues ere dose- pe n , in ic ng that 29
was a  ff ct v HIV-1 inhi i r i tif  y si il rity s rch u i g 3 s  lead t plat . Th  IC50
value of 29 was 2 µM (Figu e 3D), nd 29 s w d o y o xi y, as termin d by the cell viability
in t e CEM-GFP cell li , wh n t ste t t high st c nc ntr tio  of 25 µM (Figure 3E). These res lts
c firm d that 29 is a potent HIV-1 i hibitor, an hat i a i-HIV-1 ctivity was n t du  to ytotoxic 
eff cts n he ost ells. The e bi c i ity ata al  pr vide vid n e th t 3 is vi ble lead compound
f  developin ew l ga d to inhibit HIV-1 i fecti n via CD4.  
Most of th  comp unds coll cted from NCI d abase using the similar ty sea ch approach sh
cert i commo ubs ructures with 3. T e  compou d  were classified i to our cl sses fo  further 
st dies. The common structures of each class fication and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The c mp titive CD4 bi ing ass y r sults of anal gs f 3 (A). A ng hes  logs, 29 
how d the best binding affi y with a  IC50 alue of 4 µM (B,C). 29 in ibit  HIV-1 nfect o i  a 
dose-depend nt manner (D), a d a CellTi er Blu  assay f 29 howed a comple  lack of cytotoxicity
effect (E). 
We als  ev luated the anti-HIV-1 inf ction activity of 29 using the CEM-GFP reporter cell line. 
The GFP values were signi i antly lower f r HIV-1 infect d groups reated with 29 than th  group 
without drug treatm nt, a d the decreas of the GFP valu s were ose-d pendent, in ic i g th 29
was an effective HIV-1 nhibitor identif d y s m l r ty arch u ing 3   lead template. The IC50 
value of 29 was 2 µM (Figu e 3D), and 29 howed no cytotoxicity, a  determined by th  ell v ability 
in the CEM-GFP cell line, when teste  at the highest conc ntration of 25 µM (F gure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and th t its anti-HIV-1 ctivity was not due to cyt t xic 
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for developing ew ligands to inhibit HIV-  infection via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substructures with 3. hese compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
 
     8.87
Molecules 2018, 23, x 7 of 19 
 
Figure 3. The c petitive CD4 bindi g assay es lts  analog  of 3 (A). Am g the e nalogs, 29 
how  the b st bindi g affinity ith an IC50 val e f 14 µM (B,C). 29 i hib ted HIV-1 inf ction i  a
do e-d pendent man er (D),  a CellTi r Blue ssay of 29 showed  c mplete lack of cyt t xi ity 
effe t (E). 
We also evalu t d the nti- i tivity f 29 u i g the CEM-GFP rep r er cell l ne.
T  GFP values w re sign fica tly lower for HIV-1 infe ted gr up  treat d wi h 29 tha  t e group 
w thout d u  tr a m t, a  h ecreas  of  GFP values were o - pe dent, ating that 29
was an effectiv  HIV-1 i hi it r i ntifi d y imi ri y search using 3 s  lea  tem l t . T e IC50 
value of 29 as 2 µM (Fig  3D), nd 29 showed no ytot xicity, as determi e  by the c ll viabili y 
in the CEM-GFP cell line, wh n test d t the highest c ce trati n of 25 µM (Figure 3E). T ese results 
confirmed that 29 is a potent HIV-1 in ibi r, an  hat ts n - IV-1 activity was not due to cytotoxic 
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound
for developing new liga ds to i hibit HIV-1 infection via CD4.  
Most of the compounds collected fro  NCI database using the sim larity search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The c mmon structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2.
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Figure 3. The co titive CD4 bi ding assay results f analogs of 3 (A). Am ng t e e analogs, 29 
showe  the b t binding ffinity wit  n IC50 alue of 14 µM (B,C). 29 i hib ted HIV-1 inf ction in a
dose-d pendent m n er (D), a d  CellTiter Blu ssay of 29 showed a complete lack of cytot xi ity 
effect (E). 
W al o evaluat d he t -HIV-1 i fec  activity of 29 u ing he CEM-GFP ep r er cell line.
Th  GFP values w r  s gni cantly lower fo  H V-1 inf cted grou tre ted with 29 than the group
t ou  drug tr m t, a d the decre se  t e GFP values we e ose- ep en , c ing that 29
was an effe tiv  HIV-1 i ibi r i f e  by simil r ty s rch u ng 3 s a lead tem late. T  IC50
value f 29 was  µM (Fig  3D), a  29 sh wed no yto xicity,  d termin d by the cell viability 
in the EM-GFP cell li e, wh n teste  t the high st c ce tration of 25 µM (Figure 3E). These results 
confi med th t 29 is a p t nt HIV-1 inhibitor, a d that its nti-HIV-1 activity was n t due to ytot x c 
effects n the host cells. These bioactivity data also provide vidence that 3 is a viable lead compound
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of the comp unds collected from NCI database usi g the similarity sea c  approach share 
certain common substructures with 3. These compounds were classified into four classes fo further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The co petitiv  CD4 binding ss y re lts f a al gs of 3 (A). Am ng these analogs, 29 
showe  the best bindi g affinity with n IC50 alue f 14 µM (B,C). 29 inhib ted HIV-1 inf ction in a
dose-depe d nt manner (D), a d a CellTiter Blu as y of 29 sh wed  c mplete lack of cytotoxicity 
ff t (E). 
We al o eval a ed t nt -HIV-1 infection activity f 29 u i g he CEM-GFP rep rter ell line.
The F  valu s w r  gnif cantly low r fo HIV-1 f c  grou tre ted wi h 29 than t e g oup
witho  d ug tre tm nt, a d  ecr s of  GFP v lues w re dos -dependen , i ic ing that 29
was a  eff ct v  HIV-1 inh i r i entif d by simi rity s rch u i g 3 as  l a  te l te. The IC50 
value f 29 as 2 µM (Fig re 3D), and 29 h wed no y ot xicity, as d termin  by the cell viability 
in he EM-GFP ell li , wh n teste  at the h gh st co centr on of 25 µM (Figure 3E). These results 
confirmed that 29 is a p ten  HIV-1 inhibitor, a d hat i s anti-HIV-1 activ ty was n t d e to ytotoxic 
effects n the host ells. These bioactivity data also provide vidence t t 3 is a viable lead compound
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of the comp unds collected from NCI database usi g the similarity sea c approach share 
certain common substructures with 3. Thes  compounds were classified into our classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figur  3. The co petitiv  CD4 binding assay r sults of a a g of 3 (A). Am ng th se analogs, 29 
sh wed the best bi di g a ini y with n IC50 value of 14 µM (B,C). 29 inhib ted HIV-1 infection in a 
d se-dep d nt mann r (D), and  CellTiter Blue as y of 29 showed a complete l ck of cytotoxicity 
ffect (E). 
W al o eval a e h  n -HIV-1 infect o activi y f 29 i g he CEM-GFP repor e  cell line.
 F va ues we  signif ca tly lower f r H V-1 inf  groups tre ted wit 29 than the group
wit o  dr g tr e t, a d t e d cr s of th GFP values ere dos - ependen , in ic ing that 29
wa an ffe t v  HIV-1 i h i r i nt f d by s mil rity se rc  u i g 3 s  lea  te late. T e IC50
valu of 29 was  µM (Fig 3D), and 29 sh wed  y otoxici y, as d termin d by the cell viability 
in the CEM-GFP cel  li e, whe  teste  t the igh st c ce trat on of 25 µM (Figure 3E). These results 
co f rmed that 29 is a potent HIV-1 inhibitor, and that an i-HIV-1 ctivity was n t d e to ytot xic 
eff cts n the host ells. These bioacti ity data also provide viden e t t 3 is a viable lead compound 
f r developin  ew l ga ds to inhibit HIV-1 infection via CD4.  
Most of the comp unds coll cted from NCI database using the s milarity sea ch approach share 
certain common substructures with 3. The  compounds were classified into our classes fo  further 
st dies. The common structures of each class fication and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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We al o eva uated the anti-HIV-1 i f ction c ivit  f 29 usi g the EM-GFP r por r cell line. 
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eff ct (E). 
W  lso eval at d the t -HIV-1 inf t on ctivit  f 29 u ing  CEM-GFP rep rt r cell l . 
The GFP values w r  significantly low r for H V-1 i fect d gr  treated wi h 29 tha  t  group
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w  an ff tive HIV-1 i hibit r i ntifi  by imi rit arch using 3 as  le  t mpl t . Th  IC50
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nfirmed that 29 is a potent HIV-1 i bit r, an  at its anti-  act vity was not du  to cyt toxic 
effects n the  c lls. The  bioactivity data lso pr vide viden e th t 3 i  a vi ble lead c m ou d 
fo  developing n w liga ds to i hi it HIV-1 infec i n via CD4.  
Most of the comp unds llected fro  NCI d ba e using the similarity se rch appr ach sh  
certai  common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 10  µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 1 840 
 
     8.87 
Molecules 2018, 23, x 7 of 19 
 
Figur  3. Th co petitive D4 bin i g y res lt  of alo s of 3 (A). Amon  these analogs, 29
s owed the best bindi g affinity wit  n IC50 value of 14 µM (B,C). 29 inhibited  in ecti n in a 
d s -dependent m  (D), and a CellTiter Blue ssay f 29 sh wed a complet  lack of ytotoxicity 
ff ct (E). 
We ls eval a d t  t -HIV-1 i f on activit  f 29 u i g h  CEM-GFP repor r cell line. 
Th   values wer  signi icantly low r for H V-1 fect d gro s treat d wi h 29 than th  group
wit o t d g tr atm t, a d t e ecre se f e GFP values w re dose- p n , in ic ing that 29
was an ff tiv  HIV-1 i ibi r i tif  by simil rit rch u i g 3 s a l  t l t . T  IC50
value of 29 was  µM (Fig  3D), a d 29 s w d  yto xi ity, as d termin  b the cell vi b lity 
i  t e CEM-GFP ell li e, wh n t st  t t high st c c t tio  of 25 µM (F ure 3E). T ese r s lts 
nfirmed that 29 i  a pot nt HIV-1 i h bitor,  at its nti-HIV-1 act vity was n t d  to yt toxic 
effects n the  c lls. The e bi a tivity ata l o pr vide vidence t t 3 i  a vi ble lead c m ou d 
f  developin  n w liga ds to inhi it HIV-1 i fec i n via CD4.  
Most of the comp unds llected from NCI d base using the similarity sea ch appr ach sh  
cert i  common substructures with 3. These compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
 
     8.87 
Molecules 2018, 23, x 7 of 19 
 
Fig r  3. Th o p titiv D4 b nd ng as ay res lt of a al g of 3 (A). Among t es anal gs, 29
howed the b s  bindi g affini y w th n C50 v ue o  14 µM (B,C). 29 inhibi ed HIV-1 in ection in a 
d -dep nd t ma e  (D), nd a CellT t  Blu assay f 29 s w a comp e lack f ytotoxicity 
eff c  (E). 
We l o evalu ed  ant -HIV-1 inf tion activit  f 29 u ing th CEM-GFP rep r r cell line. 
T   v lu s w r  s gnif cantly low r fo HIV-1 f c  gro p tre t d wi  29 than t  group 
wit ou  d g tre m nt, a d  cre se  GFP values re dos - pe n , in ic ing that 29
was a  f t v HIV-1 i hi i r ntif d by si i rity arch u i g 3 s a l  t l t . T  IC50 
value f 29 as 2 µM (Fig  3D), d 29 s ow d  y o xi ity, a  rmin b he cell viability 
i  t e CEM-GFP ell li , wh n t ste  t the high st c c t tio  of 25 µM (Figure 3E). These res lts 
firmed that 29 i  a potent HIV-1 i h bitor, a d hat i s ti-HIV-1 ctivity was n t d  to ytotoxic 
effects n the  lls. The e bi a ivity ata l o pr vide vid nce t t 3 is a vi ble lead c m ound 
f  developin  new liga d to inhibit HIV-1 i fecti n via CD4.  
Most of th comp unds collected from NCI d base using the similarity sea ch appr ach sh  
cert i  common substructures with 3. Thes  compounds were classified into our classes fo  further 
studies. The common structures of each classification and CD4 bi d ng i hibition at 10  µ  are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compounds generated from th  NCI similarity search. 
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Fig re 3. T e o p t tiv D4 bi di g as y res of al g f 3 (A). Amon  thes anal gs, 29
ho the b st bindi g f i ity wi n IC50 va ue  14 µM (B,C). 29 i hibit d HIV-1 infecti n in a 
o - p den ma r (D), and a ellTi  Blu ass y of 29 s wed a compl te lack of ytotoxicity 
ff ct (E). 
W  l  val d th  a -H V-1 nf ct activit  f 29 u i g t CEM-GFP rep r  cell line. 
Th   va es w r  gnif cantly low r fo  H V-1 inf c  gro p tr t d wit  29 t an th  group
wit ou  dr g tr m nt, a d t  cre s f th  GFP v l es ere d se- p d n , in ic ing that 29
was  ff t v  HIV-1 i h i r i n if d by simil rity s rch u i g 3 s  l  t lat . T  IC50
val e f 29 w s  µM (Fig 3D), a d 29 s w d  y o xi ity, as termin d by the cell viability 
i  t  CEM-GFP ell li , wh n test  t t high st c c tr t o  of 25 µM (Figure 3E). These res lts 
firmed that 29 i  a pote t HIV-1 i hibitor, an  hat i i-HIV-1 ctivity was n t d  to ytotoxic 
eff cts n th  ost ells. The e bi a i ity ata al o pr vide vid n e t  3 is  vi ble lead compound 
f  d velopin  ew l ga d  to inhibit HIV-1 i fecti n via CD4.  
Mo t  th  comp unds coll cted from NCI d abase using the similarity sea ch approach sh  
cert i common substructures with 3. The  compounds were classified into our classes fo  further 
st dies. The common structures of each class fication and CD4 bi ding i hib tion at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compound  generated from th  NCI similarity search. 
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Fig re 3. Th  co petitive CD4 nding assay r sults f an l gs of 3 (A). A o g th s  a al gs, 29
showed the best binding ffi ity with a  IC50 value of 14 µM (B,C). 29 inhibite  HIV-1 infection in a 
dose-dependent mann r (D), and a CellTite Blue assay f 29 showed  comple e lack of cytotoxicity 
eff ct (E).
W  also evaluat d th  ant -HIV-1 i fect o  a tivity of 29 using the CEM-GFP repor er cell line.
Th  GFP values were significantly lower for H V-1 infect d gro ps treated with 29 han the group
without drug treatment, and the decreas  of the GFP values were dos - pendent, i ic ing that 29
was an effectiv HIV-1 i hibitor id ntifi d by simil rity se rch using 3 s a lead tem lat . T  IC50
value of 29 was  µM (Fig  3D), a d 29 howed no cytotoxicity, s deter ined by th cell viability
in the CEM-GFP cell line, wh n teste  t the highest c ce tratio  of 25 µM (Figure 3E). These res lts
c nfirmed that 29 is a potent HIV-1 inhibitor, and hat its anti-HIV-1 activity was not due to cytotoxic 
effects n the ost cells. The e bioactivity data also provide evidence that 3 is a vi ble lead compound 
fo  developing new ligands to inhibit HIV-  infecti n via CD4.  
Most of the compounds collected from NCI d abase using the similar ty search approach sh  
certai  common ubs ructures with 3. These c mpounds were classified into four cl sses fo  further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Fig re 3. Th  co p i ve CD4 i i g assay resu ts of l gs of 3 (A). A ong e nal gs, 29
showed th  best inding af inity wit   C50 value of 14 µM (B,C). 29 inhibited HIV-1 inf ct n in a 
dos -depend n manner (D), a a C llTi Bl e say f 29 show d  compl t  l k of cyto oxicity 
ff t (E).
We al o eval at d the nti-HIV-1 inf o  ctivity of 29 u ing e CEM-GFP rep r er c ll l .
Th  GFP values w re igni icantly lower f r HIV-1 nfected gr  treated wi h 29 t a t e group
without d g treatm t, n  h  ecre s  f he GFP values were dos - en , i ating that 29
was an effectiv HIV-1 ib t r i tifi  by imi rity rch using 3 s  lea  tem l t . T  IC50
value of 29 as 2 µM (F g  3D), d sh w d  cytot xic ty, s de rmi ed b  the cell vi bili y
in the CEM-GFP cell lin , wh n test  t t  highest c ce t tio  of 25 µM (F gure 3E). T ese res lts
c nfirmed that 29 is a potent HIV-1 i bitor, a  t at its anti- act vity was not due to cytotoxic 
effects n the  cells. The e bioactivity data a so provide vidence th t 3 i  a v able lead com ound 
fo  developing n w ligands to inhi it HIV-1 infec i n via CD4.  
Most of the comp unds llected fro  NCI d ba e using the similar ty se rch appr ach sh  
certai common ubs ruc ures wi h 3. T ese compounds were cl ssifie  into four cl sses fo  further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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Figure 3. Th  c pe iv  D4 g ass y res lt  f l gs of 3 (A). Among se n l gs, 29
showed th  b s  bindi g affinity wit   C50 value of 14 µM (B,C). 29 in ibited I -1 nf cti n in a 
do e-d pende t er (D), and a CellTit r Blu ss y f 29 s w d a compl te l ck f cyto xi ity 
ff c  (E).
W  l o eval at d th nt -HIV-1 inf o  activity of 29 ing h CEM-GFP rep er cell lin .
Th  F  value w r s gni c ntly lowe  fo  H V-1 inf cted gro  t e ted wi h 29 t an t e group
witho t d g tr a m t, and  ecre se of he GFP values were s - p d n , in ic ng that 29
was an effect v HIV-1 i ib r i tif  by simi rity rch u ing 3 s a lea  te l t . T  IC50
value f 29 as µM (Fig  3D), nd 29 sh w   y o xi ity, as d t rmin b the cell vi b lity
i  t e EM-GFP cell li , wh n test  t t high st c ce t tio  of 25 µM (F gure 3E). These res lts
c nfirmed that 29 i  a potent HIV-  inh bitor, a  t at its anti-HIV-1 act vity was n t d e to ytotoxic 
effects n the cells. The e bi activity ata a so provide vidence th t 3 i  a v ble lead com ound 
f  developin  n w liga ds to inhi it HIV-1 i fec i n via CD4.  
Most of the comp unds llected from NCI d base using the similar ty sea ch appr ach sh
cert i  common ubs ruc ures wi h 3. T ese compounds were classifie  nto four cl sses fo  further 
studies. The common structures of each classification and CD4 bi ding hibition at 100 µM are 
shown in Table 2. 
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Figu e 3. Th co p ti ive D4 g assay r sul of an l gs of 3 (A). Among anal gs, 29
sh wed the best bindi g affi ity with n C50 alue of 14 µM (B,C). 29 inhibited HIV-1 infect n in a 
o -d pen e t ner (D), a a CellTit r Blu ssay f 29 s w d a compl t  l ck f cytotoxicity 
ff t (E).
W  l o evalua d t nt -HIV-1 inf t o  activity of 29 u i g the CEM-GFP rep er cell line.
Th  F  val e w r s gnif c tly low r fo H V-1 f c gro p tre t d wi h 29 than t e group
withou  d ug tre tm nt, and e ecr se of h  GFP value  re dos - pe d n , in ic ng that 29
was a  effect v HIV-1 i hi r i ntif d by simi rity arch u i g 3 s lea  te l t . T  IC50
v l e f 29 as µM (Fig  3D), nd 29 showed  y o x ity, as rmin b the cell viability
i  t e CEM-GFP cell li , wh n teste  t the high st c ce t t o  of 25 µM (Figure 3E). These res lts
c nfirmed that 29 i  a potent HIV-1 i h bitor, a d hat i s a ti-HIV-1 activity was n t d e to ytotoxic 
effects n the s  ells. The e bi activity ata al o provide vid nce th t 3 is a v ble lead com ound 
f  developin  ew liga d  to inhibit HIV-1 i fecti n via CD4.  
Most of th  comp unds collected from NCI d base using the similar ty sea c appr ach sh  
cert i  commo  ubs ruc ures with 3. T es  compounds were classified nto our cl sses fo  further 
studies. The common structures of each classification and CD4 bi d ng i hib tion at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compounds generated from th  NCI similarity search. 
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Figu e 3. Th co titiv D4 nd ng ass y resu t of anal gs f 3 (A) Among th s anal gs, 29
s owe he st b ndi g af i ity wit n IC50 value of 14 µM (B,C). 29 i hibit d HIV-1 infect n in a 
d e-d pend t m n r (D), and a CellTit Blue y f 29 sh wed c mplet  l ck f cytot xi ity 
ff ct (E).
W  l o val a ed t n -HIV-1 inf ct activity of 29 i g the CEM-GFP rep r er cell lin .
 F  v es w r gnificantly wer fo  H V-1 f c gro p tre ted wit  29 t an the group
wit o  dr g tr m t, and t e cre s of th  GFP values re ose- pe d n , in ic ng that 29
was a  ffe t v HIV-1 i hi i r i n f d by s mil rity s rch u i g 3 s lea  te lat . T  IC50
val f 29 was  µM (Fi 3D), a d 29 s wed  o xi , as termin d by the cell viability
i  t e CEM-GFP cel li , wh  teste  t t e high st c ce tr t o  of 25 µM (Figure 3E). These res lts
c firmed that 29 is a potent HIV-1 i hibitor, a  hat i a i-HIV-1 activity was n t d e to ytotoxic 
eff cts n th  ost ells. The e bi acti ity ata al o provide vid n e t t 3 is a vi ble lead compound 
f  d velopin  ew l ga d  to inhibit HIV-1 i fecti n via CD4.  
Mo t  th  comp unds coll cted from NCI d abase using the similar ty sea ch approach sh  
cert i commo ubs ructures with 3. The  compound  were classified nto our cl sses fo  further 
st dies. The common structures of each class fication and CD4 bi d ng i hib tion at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compound  generated from th  NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6
Inhibition at 
100 μM (%) 
6 5302      5.64 
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Figure 3. The comp titive CD4 binding a y r sult  of nal gs f 3 (A). Amo g he  an logs, 29 
showed the best binding a fi ty with  IC50 v lue f 4 µM (B,C). 29 inhibit  HIV-1 ti in a
dose-dependent mann r (D), nd a C llTiter Blu  sa  of 29 owed a complet l k of ytot x ci y
effect (E). 
We also evaluated the anti-HIV-1 infecti  act vity of 29 s ng t  CEM-GFP r p rter cell li . 
The GFP values were significantly low r f r I -  i fec ed groups treated with 29 t a  t e group 
without drug treatm nt, a d t  decr ase f t e GFP values r  se-d pendent, in icat ng th t 29 
was an effective HIV-1 inhibi or identifi d by simila ity search u ing 3  a le d templ te. The I 50 
value of 29 was 2 µM (Figure D), n 29 s wed n cyto oxicity, as determined by the cell iability 
in the CEM-GFP cell lin , wh n tested at the hig st c ncentration of 5 µM (Figure 3E). Thes  results 
confirmed that 29 is a pot nt HIV-1 i hibitor, an  t ts anti-HIV-1 a ivity was ot du  t  cytot xic
effects on the host ce l . These bioactivity data also provide evidence that 3 is a viable l ad compou d 
for developing new ligands t  inhibit HIV-1 infection via CD4.  
Most of the compounds collected fr m NCI database using the simil rity se rch pproach share 
certain common substructures with 3. hese compounds w re classified int  four class s or further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
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Figur  3. Th co p ti ive CD4 bind  ass y su s f analo  f 3 (A). Amo g th e n l g , 29
sho ed the b s  b ding f i ity i n C50 valu f 14 µM (B,C). 29 i hibit d I - infect o  in a
dos -dependent man er (D), a a C llTi Bl  say f 29 show d  c ple e l k of yto xi ity 
eff t (E).
W  also evaluat d the n -HIV-1 inf c on ctivity of 29 using t e CEM-GFP rep rter c ll li . 
The GFP values  signi icantly lower f r H V-1 infected gr p  tre ted with 29 t an t e group 
without d g tr m t, nd he decr ase f the GFP values were os - n e t, d ating that 29 
was an effective HIV-1 in bit r de tified by imi rity s rch using 3 as a lead templat . Th  IC50
value of 29 as  µM (Figure 3D), nd  show  n  cyto oxicity, s de rmined b  the cell vi b lity 
in the CEM-GFP cell lin , wh n test d at t  highest c ncentr tio  of 25 µM (Figure 3E). These res lts 
c nfirmed that 29 s a pot nt HIV-1 i ibi or, a  ha ts n - I - activity was not due to cytot x c 
effects n the st cells. These bi activity ata also provide vidence th t 3 is a viable lead com ound 
for developing n w ligands to i hi it HIV-1 infecti n via CD4.  
Most of th  comp unds c llect d fro  NCI d t base using the similarity se rch appr ach sh r  
certai  common ubs ru ures wi h 3. T ese compou ds we e cl ssifie  into four cl sses fo further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The struc ures and inhibition data of compounds generated from t e NCI similarity search. 
Class I:  
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Inhibition at 
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Figure 3. The co peti iv  D4 bin as y r su t  f al s of 3 (A). A o  se an logs, 29
sho ed the b st binding af i ity wit  C50 alue f 14 µM (B,C). 29 inhibited I -  infe ti  in a
o -depe de t m er (D), a a CellTit Blu ssay f 29 how d  c mple e l ck of cyto xi ity 
ff t (E).
W  lso val a d t  ant -HIV-1 inf c on activity of 29 using th CEM-GFP rep rter cell lin . 
Th FP values w r  signi icantly lower for H V-1 fect d gro p tre ted with 29 than t e group 
without d ug tr a m t, and  decrea  of th  GFP values w re s - p n , nd c ing that 29 
was an effective HIV-1 in ibi  i e tif d by simi rity s rch u i g 3 as a lead te plat . Th  IC50 
value f 29 as  µM (Figure 3D), d 29 sh wed  y o oxicity, as d rmin d b the cell vi b lity 
i t e EM-GFP cell li e, wh n test d t t high st c ncentr tio  of 25 µM (Figure 3E). These res lts 
c nfirmed that 29 is a po n HIV-1 inhibitor, a d hat i s nti-HIV-1 activ ty was n t due to ytot x c 
ffects n he st cells. Thes  bi activity ata also provide vidence th t 3 is a vi ble lead com ound 
f r developin  n w liga ds t  inhi it HIV-1 i fecti  via CD4.  
Most of the comp unds c llected fro NCI d t base using t e similar ty sea c appr ach sh r  
cert i  common ubs r c ures wi h 3. T se compounds were classifi  nto four cl sses fo further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
able 2. The tructures and i hibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
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Figure 3. The competitive CD4 bin ng ass y r sults of analogs f 3 (A). Among these analogs, 29 
show d the b s  bin ing affi ity ith an IC50 alue f 14 µM (B, ). 29 inhibited HIV-1 infect on in a 
dose-d pendent manner (D), a  a CellTit r Blu  assay of 29 showed a com lete lack of cytot xi ity 
effect (E).
We also evaluated the anti-HIV-1 infection activity of 29 usi  t e CEM-GFP reporter cell line. 
The GFP val es were significantly lower for HIV-1 infected groups tre t d with 29 than the group 
without drug tr a ment, and the d crease o  the GFP values w r  ose-dependen , d cating that 29 
as an ef ective HIV-1 inhibitor identified by similarity search using 3 as a lead template. The C50 
v l e of 29 was 2 µM (Figure 3D), and 29 showed no cyt tox city, as determined by the cell viability
in the CEM-GFP cell line, when t sted at the ighest concentration of 25 µM (Figure 3E). These results 
co firmed that 29 is a potent HIV-  inhibitor, and that its anti-HIV-1 activity was n t due to cytot xic 
effects on the h st cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for eveloping new ligands to inhibit HIV-1 infection via CD4. 
Most of the compounds collected from NCI database using the similarity search approach share 
certai c mmon substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 bind ng inhib tion at 100 µM are 
how  in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
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Fig re 3. The o p titive D4 bin ng as y re u t of nal f 3 (A). Amon  thes an logs, 29
sh w h b st b di g f i ty w t an IC50 valu of 14 µM (B,C). 29 i ib t d HIV-1 infe t  in a
d e-d pe t m n r (D), an  CellTi Blu  as y f 29 s owed a comp te l ck f cytot xi ity 
ff ct (E).
W  l o val a d  a -HIV-1 inf ct on activity of 29 using the CEM-GFP reporter cell lin . 
Th  FP va s were signific ntly low r for H V-1 f c  gro ps tre ted wit 29 than the group 
w ho  dr g tr a m nt, and t  cr s of th  GFP val es re se- p nd n , nd cating that 29 
was a  effe t v  HIV-1 inhi itor id n ifi d by simil rity se rch usi g 3 s a lead te plat . Th  IC50 
val of 29 was  µM (Figur 3D), nd 29 s wed n  c ot xicity, as termined by the cell viability 
i t  CEM-GFP cell line, wh n tested t the highest c ncentr tio  of 25 µM (Figure 3E). These res lts 
c firmed th t 29 is a poten HIV-1 i hibitor, a d that i an i-HIV-1 tiv ty was not due to cytotoxic 
eff cts n th  ost lls. T ese bi acti ity ata also provide evid n e t t 3 is a vi ble lead compound 
f r d veloping ew l gands t  inhibit HIV-1 i fecti  via CD4.  
Most f th  compounds coll cted from NCI d tabase using the s milarity search approach sh r  
cert i commo ubs ructures with 3. The  c mpound  were classified nto our cl sses fo further 
st dies. The common structures of each class fication and CD4 bi ding inhib tion at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibit o  ata of compound  generated from th  NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6
Inhibition at 
100 μM (%) 
6 5302      5.64 
7 11840 
 
     8.87 31.77
20 649799
Molecules 2018, 23, x 8 of 19 
 
8 29117       
12.04 
9 45749       6. 0 
10 65625       
16.98 
11 72276    10.83 
12 100977
     
5.27 
13 118660
 
     11.80 
14 25 156 
      
8.47 
15 289346 
 
     15.80 
16 372920 
      
19.76 
17 37 922 
      
37.27 
18 372923 
 
     37.10 
19 642907       
31.77 
20 64979  
 
     42.79 
Class II:  
 
No. NSC No. R1 R2 R3 R4 Inhibition at 100 μM (%) 
21 347512 
    
33.51 
22 3 4633
    
39.17 
23 358 15 
    
32.87 
24 36 82 
    
45.42 
25 36 583 
    
25.79 
26 3 2083     
8.10 
27 383452 
    
51.37 
Class III:  
Molecules 2018, 23, x 7 of 19 
 
Fig r  3. The competitive CD4 binding ass y resu ts f an lo s of 3 (A). Amo g th se a logs, 29 
showed th  b st bi di g ff nity wit  a  IC50 value f 14 µM (B,C). 29 inhibit d HIV-1 infe ti  in a 
dos -dependen manner (D), an a CellTite Blue ssay of 29 showed a comple e l ck of c tot xi ity 
ff ct (E).
We al o eva ated the anti-HIV-1 infectio  activity of 29 using the CEM-GFP r port r cell lin . 
The GFP values were signific tly lower for HIV-1 nfecte  groups treated wit  29 than the roup 
without drug tr a ment, a d the decrease of the GFP values were ose-d pe den , n ating tha  29 
was an effective HIV-1 inhibitor identified by similarity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 sh wed n  cytotox city, as determined by the cell viab lity 
in the CEM-GFP cell line, when teste at the highest concentration of 25 µM (Figure 3E). Thes results 
confirmed that 29 i a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was not due to cytotoxic 
effects on the host cells. These bi activity data also provide evi ence that 3 is a viable lead compound 
for developing new ligand o inhibit HIV- infection via CD4.  
Most of the compounds collected fro  NCI databas  using t e similarity search approach share 
certain common ubs ructures with 3. These c mpounds were classified into four cl sses fo further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
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Figure 3. The co p ti iv CD4 b n i  ass y esu ts  anal  f 3 (A). Amo g th e an log , 29
sho ed the best bi ding f inity i  n C50 valu  f 14 µM (B,C). 29 inhibit d I - in cti  i  a 
dos -dep ndent man r (D), a a C llTi Bl  say f 29 show  c p e la k of y o xicity
ff t (E).
We also v l ated a ti-HIV-1 inf tion ctivity of 29 u ing e CEM-GFP rep rter c ll li .
The GFP values w r  significantly lower for HIV-1 nfecte gro ps tre ted with 29 t an the group
without dr g treatme t, d ecrease of t e GFP valu s were d s - ent, i cating that 29
was an effective HIV-1 nhib or id tified by similarity earch using 3 as a ea  templat . Th  IC50
value of 29 was 2 µM (Figure 3D), d  sh w d n  cyto oxic ty, s de rmi ed b  the cell viab lity
in the CEM-GFP cell lin , wh n teste at th  highest c ncen atio  of 25 µM (Figure 3E). T ese res lts
c nfirm d that 29 is a potent HIV-1 i h bitor, and at its anti- activity was not due to cytotoxic 
effects n th  cells. The e bioactivity da a also provide vidence th t 3 is v able lead com ou d
fo  developing new liga ds to i hibit HIV-1 inf cti n via CD4.  
Most of the comp unds collected fro  NCI ba e using the similar ty se rch appr ach sh
certai common ubs ruc ures wi h 3. T ese compounds were cl ssifie  into four cl sses fo  further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302       5.64 
7 11840 
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Figure 3. The co peti iv D4 bin i  as y s t  a alo  of 3 (A). Amo se n logs, 29
sho ed the b s  binding affi ity wi  n C50 v lue f 14 µM (B,C). 29 inhibited I -  n t  i  a 
d -depe de t m e (D), a a CellTi Blu ssay f 29 s ow d  c mpl e l ck of cy o xi ity 
ff t (E).
We l o eval at  th  anti-HIV-1 infectio activity of 29 u ing h CEM-GFP rep rter cell lin .
Th  F  value  wer  signific ntly lower for HIV-1 infected gro ps tre t d with 29 t an the group
it out drug tr a m t, a d decrease of t e GFP valu s were s - p d n , n c ng that 29
was an effect ve HIV-1 inhibi or i entif d by similarity s arch u ing 3 as a lea te plat . Th  IC50
value of 29 was 2 µM (Figure 3D), d 29 s wed  y o oxi it , as d rmin d by the cell vi b lity
i  t e CEM-GFP cell li e, wh n test t th high st c ncentr tio  of 25 µM (F gure 3E)  These res lts
c nfirmed that 29 i a potent HIV-  inhibitor, and at its anti-HIV-1 act vity was n t d e to ytotoxic 
effects n the ost cells. The e bi activity ata a o provide vidence t t 3 i  a vi ble lead compou d
f  dev lopin  n w liga ds t inhi it HIV-1 i fec i  via CD4. 
Most of the comp u ds llected from NCI d abase using the similar ty sea ch approach sh
cert i common ubs ruc ures wi h 3. T ese compounds were classifie  nto four cl sses fo further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. NSC No. R1 R2 R3 R4 R5 R6 
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100 μM (%) 
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Fig r  3. Th  omp titiv D4 b g a y es lts of anal f 3 (A). Amon  th s an logs, 29 
ho d the b st bi di g affi ity wi  n C50 a ue  14 µM (B,C). 29 inhibit d HIV-1 in t  in a 
d -d p de t ma ner (D), a a C llT  Blu ssay f 29 s ow  a c mpl l ck f cyto oxi ity
ffe t (E).
We ls ev l at d th  a ti-HIV-1 i f tion ctivity of 29 u ing t e CEM-GFP rep rter cell lin . 
Th  F  val e  w re signific tly low r for HIV-1 inf c groups tre ted with 29 t an the group 
wit ou  drug tr m nt, a d e cre se of t  GFP values ere os - pe d n , n c ng that 29 
w s a effect v  HIV-1 inhi or i entif d by similarity rch u ing 3 s a lea  te plate. The IC50 
val e of 29 was 2 µM (Figu e 3D), nd 29 s we   y o oxi ity, as rmin d b  the cell viability 
i e CEM-GFP cell li e, when teste t the high st concent tion of 25 µM (Figure 3E) These results 
c nfirmed that 29 i a potent HIV-1 i h bitor, and that i s a ti-HIV-1 activity was n t d e to ytotoxic 
ef ects n the h ells. These bi ac ivit  ata al o provide vid ce t t 3 is a v able lead com ou d 
f r d v lopin ew liga d t  inhibit HIV-1 i fectio  via CD4. 
Most of th  comp unds collected from NCI dat base using the similarity sea c appr ach share 
cert in commo ubs ruc ures with 3. T es  compounds were classified nto our cl sses fo further 
studies. The common structures of each classification and CD4 bi ding i hib tion at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibitio  ata of compounds generated from th  NCI similarity search. 
Class I:  
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Fig re 3. The o p titiv CD4 bin g as y resu s of al  f 3 (A). Amon  th s n logs, 29
ho d he t bi di g f i ity wit  IC50 a ue  14 µM (B,C). 29 in ibit d HIV-1 inf t  in a 
do e-d p d t ma er (D), an  ellTit Blu s ay f 29 s owed a compl t  l ck of y ot xi ity 
ff ct (E).
We lso val t  th  an i-HIV-1 inf cti n ac vity of 29 using t e CEM-GFP reporter cell lin .
Th  F va  were i nific nt y low r for HIV-1 inf c gro ps tre ted with 29 than the group
wit drug tr ment, a d t  cre s of th  GFP values ere ose-d pe den , n c ing that 29
was a ffect ve HIV-1 inhi i or i n f d by imil rity se rch u i g 3 s a lea  te plat . Th  IC50
v l of 29 was 2 µM (Figu e 3D), d 29 sh wed n  y o xic , as termin d by the cell viability
in th CEM-GFP cell li e, wh n teste  at t e high st c ncentr tio  of 25 µM (Figure 3E). These res lts
co firmed that 29 is a potent HIV-1 inhibitor, and hat i a i-HIV-1 activity was n t d e to ytotoxic 
eff cts n th ost ells. The e bioac i ity data also provide vid e t t 3 is vi ble lead compou d
f  d v lopin ew l ga d  t  inhibit HIV-1 infecti  via CD4.  
Mo t th  comp unds coll cted from NCI d abase using the similar ty sea c approach sh
certai commo ubs ructures with 3. The  compound  were classified nto our cl sses fo further 
st dies. The common structures of each class fication and CD4 bi d ng i hib tion at 100 µM are 
shown in Tabl  2. 
able 2. The tructures and inhibitio  ata of compound  generated from th  NCI similarity search. 
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No. NSC No. R1 R2 R3 R4 R5 R6 
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Figur  3. The competitive CD4 inding assa  r ults of a alo s of 3 (A). A ong these analogs, 29 
ho ed th  best bi ding affini y with a  IC50 value of 14 µM (B,C). 29 inhib ted  nfect on in a 
dos -dependent man er (D), and a CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluated the anti-HIV-1 infection activity of 29 using the CEM-GFP reporter cell line. 
The GFP values were significantly lower for HIV-1 infected groups treated with 29 than the group 
without drug treatment, and the decrease of the GFP values were dose-dependent, indicating that 29 
was an effective HIV-1 inhibitor identified by similarity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 showed no cytotoxicity, as determined by the cell viability 
in the CEM-GFP cell line, when tested at the highest concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibit r, and that its anti-HIV-1 activity wa  not due to cytotoxic 
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for developing new ligands to inhibit HIV-1 infection via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain c mmon substructures with 3 These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
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value of 29 was 2 µM (Figure 3D), and 29 showed no cytotoxicity, as determined by the cell viability 
in the CEM-GFP cell line, when tested at the highest concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was not due to cytot xic 
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound
for developing new ligands to inhibit HIV-1 infection via CD4.  
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Table 2. The structures and inhibition data of compounds generated from the NCI similarity search.
Class I:  
 
No. NSC o. R1 R2 3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302     5 64
7 11840 
 
     8.87 
Molecules 2018, 23, x 7 of 19 
 
Figure 3. Th co petitive CD4 i i g assay results f n l gs of 3 (A). Am ng t se analogs, 29 
showe  the best binding affinity with n IC50 value of 14 µM (B,C). 29 i hib ted HIV-1 infection in a
dose-dependent ma  (D), and a CellTiter Blue assay f 29 sh wed a complet  lack of ytotoxicity 
ffect (E). 
We als eval a d he a ti-HIV-1 nfe tion activity of 29 usi g t e CEM-GFP repor e cell li e.
T e GFP valu s were sig ifica tly l wer for HIV-1 infected gr u s treat d with 29 t an the group
without drug tre tment, and the decrease of the GFP values were dose-depe en , indic ing that 29 
was an ffectiv  HIV-1 inhibi or i entif ed by si ilarity search u i g 3 as a le d templat . T e IC50 
value of 29 was 2 µM (Figure 3D), and 29 sh wed no ytotoxicity, as d termin d by the cell viability 
in the CEM-GFP cell li e, when tested at the high st concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was n t due to ytot xic 
effects n the host cells. These bioactivity data also provide vidence that 3 is a viable lead compound
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of the comp unds collected from NCI database using the similarity sea ch approach share 
certain c mmon substructures with 3. These compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µ  are 
shown in Table 2. 
able 2. The tructures and inhibition data of compounds generated from the NCI similarity search. 
lass I:  
 
o. NSC No. R1 R2 3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 302     5 64
7 11840 
 
     8.87 39.17
23 358315
olecules 2018, 23, x 8 of 19 
 
8 291 7
 
12.04 
9 45749      6.40 
10 65625 
 
16.98 
11 72276  0 83
12 100977 
    
5.27 
13 118660 
 
   11.80 
4 251156
    
8 4
5 289346
 
  5
6 372920
  
19.76 
17 3729  
      
37.27 
18 372923 
 
     37.10 
9 64 07    
1 7
20 649799
 
42 79
Class II:  
 
No. NSC No. R1 R2 R3 R4 Inhibition at 100 μM (%) 
21 347512 
    
33.51 
22 354633 
    
39.17 
23 358315 
    
32.87 
24 361582 
    
45.42 
25 361583 
    
25.79 
26 362083     
18.10 
27 83452 
    
51.37 
Class III:  
Mol cule  2018, 23, x 8 of 19 
 
8 29117       
12.04 
9 45749       6.4  
10 65625      16.98 
11 7227       10.83 
12 100977 
     
.27 
13 11866
 
     11.8  
14 251 56 
      
8.47 
15 289346 
 
    15.80 
16 372920 
    
19.76 
17 372922 
     
37.27 
18 372923
 
     37.10 
19 642907      
31.77 
20 649799      42.79 
Class II:  
 
No. NSC No. R1 R2 R3 R4 Inhibition at 100 μM (%) 
21 347512 
    
33.51 
22 3546 3 
    
39.17 
23 358 1  
    
32.87 
24 361582 
    
45.42 
25 361583 
    
25.79 
26 362083     
18.10 
7 8345  
    
51.37 
Class III:  
Molecules 2018, 23, x 7 of 19 
 
 
Figure 3. The co petitive CD4 bi ding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 showed a co plete lack of cytotoxicity 
effect (E). 
We also evaluated the anti-HIV-1 infection activity of 29 using the CEM-GFP report r cell line. 
he GFP values were significantly l wer for HIV-1 infected groups treated with 29 than the group 
without drug treatment, and the decrease of the GFP values were dose-depende t, indicating that 29 
was an effective HIV-1 inhibitor identified by similarity search using 3 as a lead template. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 showed no cytotoxicity, as determined by the cell viability 
in the CEM-GFP cell line, when tested at the highest concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was not due to cytotoxic 
effects on the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for developing new ligands to inhibit HIV-1 infection via CD4.  
Most of the compounds collected from NCI database using the similarity search approach share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 10  µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with n I 50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 sh wed a complete lack of cytotoxicity 
effect (E). 
We also valuated the anti-HIV-1 i fection activity of 29 using the CEM-GFP reporter cell line. 
The GFP values were significantly lower for HIV-1 infected groups treated with 29 than the group 
without drug tre tment, and the decrease of the GFP values were dose-depe en , indic ing that 29 
was an effective HIV-1 inhibi or i entif ed by similarity search u ing 3 as a lead template. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 sh wed no ytotoxicity, as d termin d by the cell viability 
in the CEM-GFP cell li e, when tested at the high st concentration of 25 µM (Figure 3E). These results 
confirmed that 29 is a potent HIV-1 inhibitor, and that its anti-HIV-1 activity was t due to ytotoxic 
effects n the host cells. These bioactivity data also provide vidence that 3 is a viable lead compound 
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of the comp unds collected from NCI database using the similarity sea ch approach share 
certain common substructures with 3. These compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
able 2. The tructures and inhibition data of compounds generated from the NCI similarity search. 
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Figure 3. The compet tive CD4 b ding assay results of analogs of 3 (A). Among the e analogs, 29 
showed the be t binding a finity with an IC50 value of 14 µM (B,C). 29 i hibited HIV-1 infection n a 
dose-depende t man er (D), nd a CellTiter Blue assay of 29 showed a co lete lack of cytotoxicity 
effect (E). 
We also evaluated th  anti-HIV-1 infection ac ivity of 29 usi g the CEM-GFP report r cell line.
The GFP val es were significantly lower for HIV-1 infec ed groups treated with 29 tha  the gr up
without drug trea ment, and the d crease of the GFP valu s were dose-dep ndent, indic ting that 29
was an effecti  HIV-1 inhibitor ident fied by similarity search using 3 as a lead template. The IC50 
value of 29 was  µM (Figure 3D), and 29 showe  no cytotoxicity, a  determined by the cell viability
in the CEM-GFP cell line, wh n tested at the highest concentration of 25 µM (F g re 3E). These results
conf rmed that 29 is a potent HIV-1 inhibit r, and th t its anti-HIV-1 activity was n t due o cytotoxic
effects o the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for developing new ligands to inhibit HIV-1 infection via CD4.  
Most of th  compounds collecte  from NCI database using the si ilarity search appro ch share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
Class I:  
 
No. SC No. R1 R2 R3 R4 R5 R6 
Inhibition at 
100 μM (%) 
6 5302     5 64
7 11840 
 
     8.87 
Molec les 2018, 23, x 7 of 19 
 
Figure 3. T e co petitive CD4 bind ng assay results f analogs of 3 (A). Among these analogs, 29 
showe  the best binding affinity with n IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-d pendent manner (D), and a CellTiter Blue assay of 29 sh wed a com lete lack of cytotoxicity 
eff ct (E). 
We also evaluat d the anti-HIV-1 infection ac ivity of 29 using the CEM-GFP r porter cell line.
The GFP values were significantly lower for HIV-1 infected groups treated with 29 than the gr up
without drug tre tm nt, and the decre se of the GFP valu s were dose-dep en , indic ing that 29
was an effective HIV-1 inhibi or i entif ed by similarity search u ing 3 as a lead template. The IC50 
value of 29 was 2 µM (Figure 3D), and 29 sh we no ytotox city, as d te min d by t e cell viability
in the CEM-GFP ell li e, wh n tested at the high st con entration of 25 µM (Fig re 3E). T ese results
conf rmed that 29 is a potent HIV-1 inhib tor, and that its anti-HIV-1 activity w s n t due to ytotoxic
effects the host cells. These bioactivity data also provide vidence that 3 is a viable lead compound 
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of th  comp unds collected from NCI databas  using  si ilarity sea ch appro ch share 
certain common substructures with 3. These compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
sho ed the best binding affinity with an IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 showed a complete lack of cytotoxicity 
effect (E). 
We also evaluated th  anti-HIV-1 infection ac ivity of 29 usi g the CEM-GFP report r cell line
The GFP values were significan ly lower for HIV-1 infec ed groups treated with 29 tha  t e gr up
without drug trea ment, and the d crease of the GFP valu s were dose-dep ndent, indic ting that 29
was an effecti  HIV-1 inhibitor ident fied by similarity search using 3 as a le d template. The C50 
value of 29 was  µM (Figure 3D), and 29 showe  no cytotoxicity, a  determined by the cell viability
in the CEM-GFP cell line, wh n tested at the highest concentration of 25 µM (F g re 3E). These results
conf rmed that 29 is a potent HIV-1 inhibit r, and th t its anti-HIV-1 activity was n t due o cytotoxic
effects o the host cells. These bioactivity data also provide evidence that 3 is a viable lead compound 
for developing new ligands to inhibit HIV-1 infection via CD4.  
Most of th  compounds collecte  from NCI database using the si ilarity search appro ch share 
certain common substructures with 3. These compounds were classified into four classes for further 
studies. The common structures of each classification and CD4 binding inhibition at 100 µM are 
shown in Table 2. 
Table 2. The structures and inhibition data of compounds generated from the NCI similarity search. 
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Figure 3. The competitive CD4 binding assay results of analogs of 3 (A). Among these analogs, 29 
showed the best binding affinity with n IC50 value of 14 µM (B,C). 29 inhibited HIV-1 infection in a 
dose-dependent manner (D), and a CellTiter Blue assay of 29 sh wed a complete lack of cytotoxicity 
effect (E). 
We also evaluat d the anti-HIV-1 infection ac ivity of 29 using the CEM-GFP r porter cell line.
The GFP values were significantly lower for HIV-1 infected groups treated with 29 than t e gr up
without drug tre tm nt, and the decre se of the GFP valu s were dose-dep en , indic ing that 29
was an effective HIV-1 inhibi or i entif ed by similarity searc u ing 3 as a lead template. The IC50 
value of  was 2 µM (Figure 3D), and 29 sh we no ytotox city, as d te min d by t e cell viability
in the CEM-GFP ell li e, wh n tested at the high st con entration of 25 µM (Fig re 3E)  T ese results
conf rmed that 29 is a potent HIV-1 inhib tor, and that its anti-HIV-1 activity w s n t due to ytotoxic
effects the host cells. These bioactivity data also provide vidence that 3 is a viable lead compound 
f r developin  new liga ds to inhibit HIV-1 infection via CD4.  
Most of th  comp unds collected from NCI databas  using t  si ilarity sea ch appro ch share 
certain common substructures with 3. These compounds were classified into four classes fo  further 
studies. The common structures of each classification and CD4 bi ding i hibition at 100 µM are 
shown in Table 2. 
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similarity indices in the space surrounding each of the molecules in the dataset [47,48]. The statistical
results generated from the leave-one-out (LOO) cross validation of the CoMFA/CoMSIA models for
CD4 binding activity are shown in Table 3, which lists the partial least squares (PLS) statistical results
of the CoMFA/CoMSIA with a determined optimum number of components (ONC), cross-validated
correlation coefficient (q2), non-cross-validation correlation coefficient (r2), standard error of the
estimate (SEE) and the F value. The CoMFA model is derived from three components, showed a q2
of 0.624, a r2 of 0.961, a SEE of 0.145 and an F value of 141.287, and the CoMSIA model derived from
4 components, showed a q2 of 0.732, a r2 of 0.973, a SEE of 0.124, and an F value of 127.654. In further
cross-validation of the CoMFA/CoMSIA models, the CoMFA mean q2 values of the leave-many-out
(LMO10 and LMO5) cross-validation were 0.630 and 0.561, respectively. The average r2 and SEE of
100 runs of bootstrapping analysis were 0.969 and 0.122. The CoMSIA mean q2 values of LMO10 and
LMO5 cross-validation were 0.736 and 0.685, respectively. The average r2 and SEE of the 100 runs of
bootstrapping analysis were 0.985 and 0.085. The values of the bootstrap r2 confirmed further that
the CoMFA/CoMSIA models in our studies were both good models for 3D-QSAR studies. All these
parameters indicated a satisfactory internal predictive ability of the model.
Table 3. Statistical results of the CoMFA/CoMSIA models.
PLS Statistics CoMFA CoMSIA
Optimum number of components (ONC) 3 4
q2 0.624 0.732
r2 0.961 0.973
SEE 0.145 0.124
F 123.938 127.654
Field contribution%
Steric 49.5 22.3
Electrostatic 50.5 10.2
Hydrophobic 23.0
Hydrogen bond donor 22.7
Hydrogen bond acceptor 21.8
For a further evaluation study, the CoMFA/CoMSIA models were employed to predict the activity
of the test set, and the result was compared with the experiment data. The experimental and predicted
data with the residuals are listed in Table 4, and the relationship between the experimental and
predicted activity values of the training set and the test set are depicted in Figure 5. The predicted
activity values were in good agreement with the experimental data. The CoMSIA model was better
than CoMFA model when compared with the PLS parameters and residuals listed in Tables 3 and 4.
Therefore, we chose the CoMSIA model for further discussion of the 3D-QSAR results.
To visualize the fields effects of the CoMSIA model, 3D contour maps in Figure 6 were generated
from the SYBYL-X program, the data was transformed using from % inhibition at 100 micromolar
concentration, and the transformed data was named as pIn. 3 was selected as a reference and overlaid
in the maps, as it is the most active compound in the training and test sets. In the CoMSIA contour
maps, various (steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor)
characters of the compounds were collected, and they contributed 22.3%, 10.2%, 23.0%, 22.7%, and
21.8%, respectively, to the interaction of compounds listed in Table 4.
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Table 4. Experimental and predicted CD4 competitive binding inhibition of compounds in training
and test sets by CoMFA/CoMSIA.
No
PInhibition a
(Experimental Data)
CoMFA CoMSIA
PInhibition a
(Predicted Data) Residual
PInhibition a
(Predicted Data) Residual
3 5.273 5.124 0.149 5.215 0.058
6 2.762 2.777 −0.015 2.586 0.176
7 2.988 3.203 −0.215 3.236 −0.248
8 b 3.136 2.934 0.202 2.731 0.405
9 2.835 2.905 −0.07 2.911 −0.076
10 3.311 2.934 0.377 3.125 0.186
11 b 3.084 2.905 0.179 2.915 0.169
12 2.745 2.876 −0.131 2.793 −0.048
13 b 3.126 3.342 −0.216 3.075 0.051
14 2.966 2.916 0.05 2.965 0.001
15 3.273 3.269 0.004 3.223 0.050
16 3.391 3.330 0.061 3.304 0.087
17 3.774 3.775 −0.001 3.752 0.022
18 b 3.771 3.436 0.335 3.430 0.341
19 b 3.668 2.940 0.728 2.972 0.696
20 3.874 3.755 0.119 3.846 0.028
21 3.702 3.872 −0.170 3.651 0.051
22 b 3.809 3.837 −0.028 3.587 0.222
23 b 3.690 3.886 −0.196 3.684 0.006
24 3.920 4.037 −0.117 3.834 0.086
25 3.541 3.531 0.010 3.517 0.024
26 3.344 3.360 −0.016 3.503 −0.159
27 4.024 3.972 0.052 3.974 0.050
28 b 4.566 3.722 0.844 4.206 0.360
29 4.763 4.819 −0.056 4.841 −0.078
30 2.841 2.780 0.061 2.928 −0.087
32 3.400 3.493 −0.093 3.523 −0.123
a The experimental and predicted data of CD4 competitive binding inhibition was presented as -ln. b Test set.
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Figure 6. The contour maps of 3D-QSAR model show: (A) the steric bulk favored (green) and steric
bulk disfavored (yellow) regions; (B) positive charge desirable (blue) and negative charge desirable
(red) regions; (C) hydrophobicity desirable (yellow) and hydrophobicity undesirable (white) regions;
(D) hydrogen bond donor desirable (cyan), hydrogen bond donor undesirable (purple), hydrogen
bond acceptor desirable (magenta), and hydrogen bond acceptor undesirable (red) regions.
The yellow contour of the CoMSIA steric contour map (Figure 6A) near positions 6 and 7 of the
3-oxo-3H-xanthen ring shows that these positions are sterically unfavorable regions (i.e., compound 32),
and propanoic acid at 3-position of 3-oxo-3H-xanthene ring is also an unfavorable substituent group.
This steric contour map agreed with the docking model of 3 shown in Figure 1A, which demonstrated
that these positions can interact with residues in the cavity of CD4. These observations indicated that
modifications of these compounds with lager substituent groups should be avoided at these positions.
The electrostatic contour map of the CoMSIA model (Figure 6B) showed that the electronegative
groups were favored near the 2, 5 positions of the 3-oxo-3H-xanthene ring, and another electronegative
group was favored near the carboxyl of the propanoic acid substituent. This was consistent with
the increased activity of compounds 24–27, compared with compounds 14–16. The electropositive
region was found in the cyclohexa-2,5-dien-1-one region. In Figure 6C, the yellow contour indicates a
favorable hydrophobic interaction region near the 3, 4, 6, 7 positions of the 3-oxo-3H-xanthene ring.
These contours can explain the decreases in the activity of compounds 32 and 24–27 when compared
with compound 3. The white contour showed an unfavorable hydrophobic interaction region near
the 4 position of the 3-oxo-3H-xanthene ring. Figure 6D shows the contour map of the hydrogen
bond donor/acceptor. The magenta contour represents a desirable hydrogen bond acceptor and it
agreed with the interaction model shown in Figure 1D. The propionyloxy group of 3 can form three
hydrogen bonds with the Phe26, Asn39, and Gln40 residues of CD4, and Asn39 and Gln40 are both
critical residues in the procedure of the interaction between CD4 and gp120. The magenta contour
near the 1 and 2 position represents an undesirable hydrogen bond, which agreed with the interaction
model for CD4 and gp120 where the H atoms at the 1 and 2 positions did not contribute to forming
any hydrogen bond with the receptor.
Based on the analysis of CoMSIA contour maps, our bioassay data agree well with the 3D-QSAR
model, and provide useful information for the new activity of predictable compounds that are designed
from the template 3. Furthermore, based on the bioassay data of 3 and 29, the contour maps can help
design anti-HIV-1 entry inhibitors from the template 3.
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3. Discussion
CD4 is critical in the process of HIV-1 invasion into its host cells, and blocking the interaction
of CD4 and gp120 can significantly inhibit HIV-1 entry into host cells [52]. We investigated new
HIV-1 entry inhibitors via CD4 by employing a structure-based virtual screening approach to dock
compounds from the NCI diversity data set to some critical residues of the cavity of CD4. Among the
docked top-score compounds generated from this virtual screening study, 3 showed strong competitive
binding affinity with CD4, and good HIV-1 entry inhibition activity without showing cytotoxicity.
The calculated properties of 3 showed that: (1) there are four hydrogen bond donors; (2) there are
six hydrogen bond acceptors; (3) the molecular weight is 316.27 Daltons; (4) the logP is −1.335; and
(5) the number of rotatable bonds is three. All five properties of 3 meet the Lipinski’s rule of five
(i.e., RO5, specifically MWT < 500, logP < 5, H-bond donors < 5, H-bond acceptors < 10, rotatable
bond < 10) [53]. Combined with the bioassay data, 3 was found to be a drug-like compound and a
viable lead with good bioactivity and no cytotoxicity. Considering the characteristics of its molecular
structure, some previous publications have indicated that 3 at a high concentration (100 µM) could
inhibit the growth of various cancer cell lines by increasing the intracellular reactive oxygen species
(ROS) level [54,55]. Based on our bioassay data, especially our PBMC cell viability assay results, 3
did not show an ability to affect cell growth at the concentrations (≤150 µM) used in our bioassays
(Figure 2D). This finding demonstrated that the ROS mechanism may not be the reason for why 3 acts
as an HIV-1 inhibitor. The chemical structure of 3 also suggests that additional structurally similar
compounds can be discovered that can act as potent CD4-binding ligands. Our data indicated that 3
could be a promising compound for the development of new HIV-1 entry inhibitors that act via CD4,
and that other structurally similar compounds can be discovered based on the chemical structure of
3. According to the data published by Robert J. Fisher et al. [45], 29 could also bind to NC-p7, and
contribute to inhibition of HIV-1 infection. Although 3 was regarded as an inactive or less effective
(0–49% protection) compound when evaluated in their anti-HIV-1 assay, our data revealed another
function of 3 and 29, as these two compounds could also bind to CD4 (the primary receptor of gp120),
and may therefore act as potential dual-targeting agents to inhibit HIV-1 infection. Support for this idea
was provided by two advanced anti-HIV-1 infection assays: recording the fluorescence value change of
infected CEM-GFP cells, and determining the intracellular p24 levels in the PBMCs. The relationship of
ligand structure and CD4 binding activity was investigated in more detail with the 3D-QSAR method.
Twenty-seven compounds generated by a similarity search with the lead compound 3 were used to
build 3D-QSAR models. CoMFA and CoMSIA models obtained based on ligand alignment both had
high q2 and r2 values (both greater than 0.5) and small standard errors of estimates. The models were
also validated by LMO cross-validation, bootstrapping, and activity prediction of the test set. All the
validations confirmed the models as being reliable and with a high predictive ability. The chemical
interpretation of the contour maps generated by CoMSIA agreed well with the changes in the chemical
structures and the bioactivity values of the compounds. We also investigated that all our compounds
that showed a greater than 30% level of inhibition, using the PubChem database and online literature
searches for any reported bioactivity and targets. The results were complicated, as compounds 3 and 29
had been reported as being active in several bioassays and multitargets; the active results and targets
(Hsp70; RAPGEF4; GAPDH; RNASEH1) were fewer for 29 than for 3. However, other compounds
had even fewer or no reported bioactivities. Some of these reported compounds were focused on
anticancer screening or antimicrobial assays without targeting a specific receptor. Since the pan-assay
interference compounds (PAINS) filter was first reported, it has become a common component of the
triage process in biological screening [56]. Based on the PAINS filter results, some of our compounds
(3, 28 and 29) failed to pass, and other compounds that came from similarity searches and that were
used in establishing 3D-QSAR models all passed the filter (Table 5). Recently, a large-scale analysis
of PAINS alerts was reported, indicating that computational PAINS filters may inappropriately flag
some compound classes, creating the potential for incorrect prediction. In fact, 87 Food and Drug
Administration (FDA) approved drugs contained PAINS alerts. The current recommendation is that
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conclusions should be drawn only after conducting orthogonal experiments. [57]. Based on theory,
published large-scale analysis results, and our results reported here, some of our compounds could
pass a PAINS filter and show bioactivity based on a compound that failed to pass the filter. This leads
us to consider the advantage of our 3D-QSAR models, which could help future studies to avoid failing
the PAINS filter, and that could provide higher specificity and lower risk based mainly on class I and
class II compounds (Table 2).
Table 5. The investigation results based on PubChem database and the PAINS filter.
No. NSC No. Bioassay (Active) a PAINS Filter b
17 372922 1 (anticancer screen) PASS
18 372923 4 (antimicrobial assay; histone lysine methyltransferase G9ainhibitor; SWI/SNF chromatin remodeling complex inhibitor) PASS
19 642907 7 (Grb2; HRAR1; p56 lck tyrosine kinase; Fyn protein kinase;phospholipase C gamma PASS
20 649799 NONE PASS
21 347512 5 (all for anti-cancer screens in mice using different models) PASS
22 354633 1 (anticancer drug screen. Data for tumor model P388Leukemia in mice) PASS
23 358315 NONE PASS
24 361582 NONE PASS
25 361583 NONE PASS
26 362083 NONE PASS
27 383452 4 (anticancer drug screen in mice, fructose-bisphosphatealdolase inhibitor) PASS
a The contents in the bioassay column are presented as “reported active bioassay number (bioassays names or
functions)”, if none was reported, a “NONE” presents. b PAINS was evaluated using the function of the PAINS
filter in SYBYL-X. A “PASS” means a compound passes through the PAINS filter.
In conclusion, the results from virtual screening, CD4 competitive binding assays, and HIV-1
entry inhibition assays, together with the 3D-QSAR models, can guide the use of molecular databases
for the discovery of new CD4 ligands that inhibit HIV-1 entry. The lead compound 3 is an effective
template for the identification of additional HIV-1 entry inhibitors. The mechanistic study using
the 3D-QSAR method provided valuable insights into the structure-activity relationship of 3 and
its analogs. Our 3D-QSAR models can also be used to predict the activity of new small molecules
designed based on 3 prior to biological testing, making these models be a valuable tool for optimizing
lead compounds with higher activities.
4. Materials and Methods
4.1. Molecular Modeling and Virtual Screening
The molecular modeling and virtual screening were performed using the Surflex-Dock module
implemented in the SYBYL-X 2.1 program (Tripos Inc., St. Louis, MO, USA). Before the docking
procedures, water molecules and other ligands were removed from the crystal structure (PDB:
1GC1 [21]), and energy minimization was performed. The NCI diversity dataset, which contains
1,974 diversity compound structures, was selected for the virtual screening study and prepared
using the preparation protocol of Surflex-for-searching in the ligand structure preparation tool.
The protomol (an idealized active site ligand to generate putative poses of molecules [58]) was
generated, selecting the critical amino acids (residues 29, 35, 40–49) in the interaction of CD4
and gp120 [21,59]. In the docking procedure, the minimization was performed pre-dock and
post-dock. A total of 20 poses were generated from each docked ligand. Forty compounds of
top-ranking total scores were selected for further bioassays. All compounds were ordered from
the Division of Cancer Treatment & Diagnosis (DCTD) of the National Cancer Institute (NCI) (website:
https://dtp.cancer.gov/organization/dscb/obtaining/vialed.htm) [60].
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4.2. CD4 Competitive Binding Assay
The SUP-T1 cells were cultured in RPMI1640 medium supplemented with 10% (v/v) fetal bovine
serum (FBS), 100 IU penicillin, 0.1 mg/mL streptomycin, and 2 mM L-glutamine. After collecting and
washing twice with fluorescence activated cell sorting (FACS) buffer (0.5% BSA, 0.05% sodium azide
in PBS) by centrifugation, SUP-T1 cells were seeded in a 96-well v-bottom plate at 5 × 105 cells/well.
The supernatant was discarded by centrifugation and the cell pellet was resuspended with 50 µL
various 2× concentrations of test compounds and 50 µL fluorescein isothiocyanate (FITC) labeled
anti-human CD4 antibody (RPA-T4 clone, BioLegend, San Diego, CA, USA). The plate was incubated
for 40 min on ice. After incubation, the cells were washed twice with FACS buffer by centrifugation,
and then resuspended with the assay buffer. The FACS buffer was added at a volume of 50 µL per well.
The fluorescence (485EX/528EM) was recorded using a Synergy II plate reader (BioTek Instruments,
Inc., Winooski, VT, USA). Experimental data were generated in duplicate each time, and from at least
three independent experiments. The mean values of fluorescence were normalized and expressed as a
percentage of the control group values. Binding curves and IC50 values were calculated by GraphPad
Prism 7 (GraphPad Software Inc., La Jolla, CA, USA) and presented as the mean ± SEM.
4.3. Peripheral Blood Mononuclear Cell (PBMC) Isolation
Blood samples were collected from healthy donors and diluted with an equal amount of 1×
PBS. Approximately 15 mL Ficoll was transferred to a sterile 50 mL tube, and then overlaid with
15 mL diluted blood. After centrifugation (Centrifuge 5810R, Eppendorf, Hamburg, Germany) at
1800 rpm for 30 min at room temperature, the PBMCs were obtained and washed twice with 40 mL
1× PBS by centrifugation (1100 rpm, 10 min for each time) at room temperature. Cell pellets were
resuspended in 50 mL RPMI 1640 supplemented with 10% FBS and 100 µg/mL Phytohemagglutinin
(PHA, Sigma-Aldrich, St. Louis, MO, USA) and cultured for 24 h at 37 ◦C with 5% CO2. Thereafter,
PBMCs were continuously cultured in RPMI 1640 medium containing 10% FBS and 5 IU/mL human
Interleukin-2 (hIL-2, Roche Diagnostics, Basel, Switzerland).
4.4. Anti-HIV-1 Infection Assay
The CEM-GFP cells were obtained from the NIH AIDS program (NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: CEM-GFP Cells from Dr. Jacques Corbeil [50]) and cultured in
RPMI 1640 medium containing 10% FBS, 1% penicillin-streptomycin (Life Technologies, Carlsbad,
CA, USA), 1% 200 mM L-glutamine (Mediatech-VWR, Aurora, CO, USA), and 500 µg/mL G418
(BioPioneer Inc, San Diego, CA, USA). After collecting and counting, the CEM-GFP cells were infected
with HIV-1 NL4-3 strain (MOI 0.01) at 37 ◦C for 2–3 h, cells were then washed twice with PBS, and
105 cells/well were seeded into a 96-well plate in the presence of different concentrations of test
compounds. After culturing at 37 ◦C with 5% CO2 for 4 or 5 days, the GFP fluorescence (485EX/528EM)
was measured using a Synergy II microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
4.5. Anti-HIV-1 Entry Assay
The Anti-HIV-1 entry assay was performed by measuring intercellular p24 antigen. Before the
infection, PBMCs (2.5× 106 cells/mL) were added into 96-well plates at 100 µL/well, then co-incubated
with compounds of various concentrations for 2 h. PBMCs were then washed twice with PBS and
infected with the NL4-3 strain of HIV-1 at an MOI of 0.02 for 2 h at 37 ◦C with 5% CO2 (CO2 incubator,
Eppendorf, Hamburg, Germany). After two washes with PBS (1200 rpm, 20 ◦C, 5 min), the cells
were re-suspended in 100 µL complete medium and incubated for 24 h. Subsequently, the PBMCs
were washed and resuspended in 100 µL/well lysis buffer containing 1% protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO, USA). The intercellular p24 antigen was measured according to the
protocol provided with the HIV-1 ELISA kit (PerkinElmer Inc. Waltham, MA, USA).
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4.6. PBMC Viability Assay
In addition to the anti-HIV assays described above, the same numbers of PBMCs were seeded
and treated with the test compounds for the same periods. After a 24 h incubation at 37 ◦C, the cell
viability was determined using the CellTiter-Blue (Promega Co., Madison, WI, USA) cell viability assay.
The fluorescence (560EX/590EM) was recorded using a Synergy II microplate reader.
4.7. Compound Structural Similarity Search
For more chemical structures similar to compounds that were identified from the NCI diversity
database, we conducted a similarity search study using the enhanced NCI database browser 2.2
(https://cactus.nci.nih.gov/ncidb2.2/) [61]. We obtained 40 more compounds with >90% Tanimoto
index (which is superior to the Euclidean distance in 2D-fragment based similarity searching) from the
NCI. Subsequently, competitive CD4 binding assays were performed to identify compounds that can
bind to CD4.
4.8. 3D-QSAR Study
The 27 compounds involved in 3D-QSAR study were generated from the structure similarity
search listed in Table 2 and the lead compound 3 in Table 1. Molecules that had no bioactivity and
did not share a common scaffold were discarded. All ligands’ 3D structures were constructed using
the Sketch Molecule function in SYBYL-X software. Gasteiger-Hückel charges were employed to
calculate the partial atomic charges, and a TRIPOS force field was used for energy minimization with a
convergence criterion of 0.05 kcal/mol·Å. The total compounds were divided into a training set and a
test set.
Subsequently, molecular alignment was performed to obtain valid and reliable 3D-QSAR
models [62]. In this study, 3, which had the most potent inhibitory activity was chosen as the template
molecule to perform the molecular alignment by using the database align function in the SYBYL-X
program. Based on the molecular alignment, CoMFA/CoMSIA models were developed for the aligned
molecular data set. In this study, five molecular fields were calculated: steric, electrostatic, hydrophobic,
hydrogen bond donor, and hydrogen bond acceptor. CoMSIA molecular fields were calculated using
a sp3 carbon probe atom carrying a charge of +1.0, and an attenuation factor α of 0.3 using default
settings in SYBYL.
To generate statistically significant 3D-QSAR models, a PLS regression was carried out. The LOO
cross-validation analysis was performed to determine the ONC and q2. After that, non-cross-validation
analysis was performed with a threshold column filtering of 2.0 kcal/mol to generate the optimally PLS
regression models for CoMFA/CoMSIA. The r2, SEE, and F ratio between the variances of experimental
and predicted activity values were obtained.
To further evaluate the statistical significance of the derived models, additional cross-validation
analyses were performed using groups in the training set. The CoMFA and CoMSIA models were
further analyzed by additional rigorous statistical cross-validation, using 10 and five groups in the
training set, and each cross-validation process was repeated 25 times. Subsequently, a bootstrapping
analysis for 100 runs was performed to measure the bias of the original calculations. In addition,
the external predictive ability of the CoMFA/CoMSIA model was assessed by prediction the
activity of the test set and compared with the experiment data. After the evaluation of 3D-QSAR
model, contour maps of all fields were constructed with default values of 80% favored and 20%
disfavored contributions.
4.9. Data and Statistical Analysis
Statistical analysis was performed using a one-way ANOVA (GraphPad Software: GraphPad
Prism 7 for Windows, GraphPad Software Inc., La Jolla, CA, USA). Average values were expressed
as mean ± SD or SEM, n > 3. The results of calcium influxes/effluxes and Western blots were
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representatives of at least of three independent experiments. A P value less than 0.05 was considered
statistically significant. * p value < 0.05, ** p value < 0.005, *** p value < 0.0005.
Author Contributions: C.Z. performed the virtual screening, biological experiments, and wrote the manuscript.
H.Z. and L.S.H. performed part of CD4 binding assays and anti-HIV-1 assays. S.Z. performed the virtual screening
and Y.X. helped in the analysis of the data. X.-Q.Z. and R.T.S. participated in the design of the biological assays
and the discussion of the data. J.A., Z.H., and X.Y. supervised the work and revised the manuscript.
Funding: This work was supported by grants from the National Institutes of Health (GM 57761).
Acknowledgments: This work was supported by grants from the National Institutes of Health (GM 57761, to Z.H
and J.A.), and the California Institute for Regenerative Medicine (to Z.H.). C.Z. was supported in part by the
China Scholarship Council. We thank the NIH AIDS Reagent Program, Division of AIDS, NIAID, and Jacques
Corbeil for providing the CEM-GFP cell line.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.;
Vezinet-Brun, F.; Rouzioux, C.; et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for
acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868–871. [CrossRef] [PubMed]
2. Hoover, D.R.; Graham, N.M.; Chen, B.; Taylor, J.M.; Phair, J.; Zhou, S.Y.; Munoz, A. Effect of CD4+ cell count
measurement variability on staging HIV-1 infection. J. Acq. Immun. Def. Synd. 1992, 5, 794–802. [CrossRef]
3. Bartlett, J.A.; DeMasi, R.; Quinn, J.; Moxham, C.; Rousseau, F. Overview of the effectiveness of triple
combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001, 15, 1369–1377. [CrossRef]
[PubMed]
4. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.;
Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency
virus infection. N. Engl. J. Med. 1998, 338, 853–860. [CrossRef] [PubMed]
5. Flexner, C. HIV drug development: The next 25 years. Nat. Rev. Drug Discov. 2007, 6, 959–966. [CrossRef]
[PubMed]
6. Clavel, F.; Hance, A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350, 1023–1035. [CrossRef] [PubMed]
7. De Cock, K.M.; Brun-Vezinet, F.; Soro, B. HIV-1 and HIV-2 infections and AIDS in West Africa. AIDS 1991, 5.
[CrossRef] [PubMed]
8. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS pandemic. CSH Perspect. Med. 2011, 1, a006841.
[CrossRef] [PubMed]
9. Wilen, C.B.; Tilton, J.C.; Doms, R.W. HIV: Cell binding and entry. CSH Perspect. Med. 2012, 2, a006866.
[CrossRef] [PubMed]
10. Freeman, M.M.; Seaman, M.S.; Rits-Volloch, S.; Hong, X.G.; Kao, C.Y.; Ho, D.D.; Chen, B. Crystal Structure of
HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. Structure 2010, 18, 1632–1641.
[CrossRef] [PubMed]
11. Zimmermann, K.; Liechti, T.; Haas, A.; Rehr, M.; Trkola, A.; Gunthard, H.F.; Oxenius, A. The orientation of
HIV-1 gp120 binding to the CD4 receptor differentially modulates CD4+ T cell activation. J. Immunol. 2015,
194, 637–649. [CrossRef] [PubMed]
12. Sattentau, Q.J.; Moore, J.P. Conformational changes induced in the human immunodeficiency virus envelope
glycoprotein by soluble CD4 binding. J. Exp. Med. 1991, 174, 407–415. [CrossRef] [PubMed]
13. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Cara, A.; Gallo, R.C.; Lusso, P. The V3 domain of the HIV-1
gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 1996, 2,
1244–1247. [CrossRef] [PubMed]
14. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. CC CKR5:
A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272,
1955–1958. [CrossRef] [PubMed]
15. Berger, E.A.; Doms, R.W.; Fenyo, E.; Korber, B.T.; Littman, D.R.; Moore, J.P.; Sattentau, Q.J.; Schuitemaker, H.;
Sodroski, J.; Weiss, R.A. A new classification for HIV-1. Nature 1998, 391, 240. [CrossRef] [PubMed]
Molecules 2018, 23, 3036 18 of 20
16. Antell, G.C.; Dampier, W.; Aiamkitsumrit, B.; Nonnemacher, M.R.; Jacobson, J.M.; Pirrone, V.; Zhong, W.;
Kercher, K.; Passic, S.; Williams, J.W.; et al. Utilization of HIV-1 envelope V3 to identify X4- and R5-specific
Tat and LTR sequence signatures. Retrovirology 2016, 13, 32. [CrossRef] [PubMed]
17. Schroeder, S.; Kaufman, J.D.; Grunwald, M.; Walla, P.J.; Lakomek, N.A.; Wingfield, P.T. HIV-1 gp41
transmembrane oligomerization monitored by FRET and FCS. FEBS Lett. 2018, 592, 939–948. [CrossRef]
[PubMed]
18. Mamede, J.I.; Cianci, G.C.; Anderson, M.R.; Hope, T.J. Early cytoplasmic uncoating is associated with
infectivity of HIV-1. Proc. Natl. Acad. Sci. USA 2017, 114, 7169–7178. [CrossRef] [PubMed]
19. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science
1998, 280, 1884–1888. [CrossRef] [PubMed]
20. Clayton, L.K.; Sieh, M.; Pious, D.; Reinherz, E.L. Identification of human CD4 residues affecting class II MHC
versus HIV-1 gp120 binding. Nature 1989, 339, 548–550. [CrossRef] [PubMed]
21. Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120
envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998,
393, 648–659. [CrossRef] [PubMed]
22. Capon, D.J.; Ward, R.H. The CD4-gp120 interaction and AIDS pathogenesis. Annu. Rev. Immunol. 1991, 9,
649–678. [CrossRef] [PubMed]
23. Peterson, A.; Seed, B. Genetic analysis of monoclonal antibody and HIV binding sites on the human
lymphocyte antigen CD4. Cell 1988, 54, 65–72. [CrossRef]
24. Qian, K.; Morris-Natschke, S.L.; Lee, K.H. HIV Entry Inhibitors and Their Potential in HIV Therapy. Med. Res.
Rev. 2009, 29, 369–393. [CrossRef] [PubMed]
25. Liu, T.; Huang, B.; Zhan, P.; De Clercq, E.; Liu, X. Discovery of small molecular inhibitors targeting HIV-1
gp120-CD4 interaction drived from BMS-378806. Eur. J. Med. Chem. 2014, 86, 481–490. [CrossRef] [PubMed]
26. Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D.L.;
Huang, S.; Zhao, F.; et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-
(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120
interactions. J. Med. Chem. 2003, 46, 4236–4239. [CrossRef] [PubMed]
27. Lalezari, J.P.; Latiff, G.H.; Brinson, C.; Echevarria, J.; Trevino-Perez, S.; Bogner, J.R.; Thompson, M.; Fourie, J.;
Sussmann Pena, O.A.; Mendo Urbina, F.C.; et al. Safety and efficacy of the HIV-1 attachment inhibitor
prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b,
randomised controlled trial. Lancet HIV 2015, 2, 427–437. [CrossRef]
28. Nettles, R.E.; Schurmann, D.; Zhu, L.; Stonier, M.; Huang, S.P.; Chang, I.; Chien, C.; Krystal, M.;
Wind-Rotolo, M.; Ray, N.; et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an
oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J. Infect. Dis. 2012, 206, 1002–1011. [CrossRef]
[PubMed]
29. Madani, N.; Schon, A.; Princiotto, A.M.; Lalonde, J.M.; Courter, J.R.; Soeta, T.; Ng, D.; Wang, L.; Brower, E.T.;
Xiang, S.H.; et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.
Structure 2008, 16, 1689–1701. [CrossRef] [PubMed]
30. Curreli, F.; Kwon, Y.D.; Zhang, H.; Yang, Y.; Scacalossi, D.; Kwong, P.D.; Debnath, A.K. Binding mode
characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.
Antimicrob. Agents Chemother. 2014, 58, 5478–5491. [CrossRef] [PubMed]
31. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A.K. Identification of
N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that
prevent gp120 binding to CD4. Virology 2005, 339, 213–225. [CrossRef] [PubMed]
32. Curreli, F.; Do Kwon, Y.; Zhang, H.T.; Scacalossi, D.; Belov, D.S.; Tikhonov, A.A.; Andreev, I.A.; Altieri, A.;
Kurkin, A.V.; Kwong, P.D.; et al. Structure-Based Design of a Small Molecule CD4-Antagonist with Broad
Spectrum Anti-HIV-1 Activity. J. Med. Chem. 2015, 58, 6909–6927. [CrossRef] [PubMed]
33. LaLonde, J.M.; Elban, M.A.; Courter, J.R.; Sugawara, A.; Soeta, T.; Madani, N.; Princiotto, A.M.; Do Kwon, Y.;
Kwong, P.D.; Schon, A.; et al. Design, synthesis and biological evaluation of small molecule inhibitors of
CD4-gp120 binding based on virtual screening. Bioorg. Med. Chem. 2011, 19, 91–101. [CrossRef] [PubMed]
34. Melillo, B.; Liang, S.; Park, J.; Schon, A.; Courter, J.R.; LaLonde, J.M.; Wendler, D.J.; Princiotto, A.M.;
Seaman, M.S.; Freire, E.; et al. Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry
Inhibition. ACS Med. Chem. Lett. 2016, 7, 330–334. [CrossRef] [PubMed]
Molecules 2018, 23, 3036 19 of 20
35. Pennings, P.S. HIV Drug Resistance: Problems and Perspectives. Infect. Dis. Rep. 2013, 5, e5. [CrossRef]
[PubMed]
36. Rusconi, S.; Moonis, M.; Merrill, D.P.; Pallai, P.V.; Neidhardt, E.A.; Singh, S.K.; Willis, K.J.; Osburne, M.S.;
Profy, A.T.; Jenson, J.C.; et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human
immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 1996, 40, 234–236. [CrossRef]
[PubMed]
37. Yang, Q.E.; Stephen, A.G.; Adelsberger, J.W.; Roberts, P.E.; Zhu, W.M.; Currens, M.J.; Feng, Y.X.; Crise, B.J.;
Gorelick, R.J.; Rein, A.R.; et al. Discovery of small-molecule human immunodeficiency virus type 1 entry
inhibitors that target the gp120-binding domain of CD4. J. Virol. 2005, 79, 6122–6133. [CrossRef] [PubMed]
38. Jacobson, J.M.; Kuritzkes, D.R.; Godofsky, E.; DeJesus, E.; Larson, J.A.; Weinheimer, S.P.; Lewis, S.T.
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly
TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
Antimicrob. Agents Chemother. 2009, 53, 450–457. [CrossRef] [PubMed]
39. Iacob, S.A.; Iacob, D.G. Ibalizumab Targeting CD4 Receptors, an Emerging Molecule in HIV Therapy.
Front. Microbiol. 2017, 8, 2323. [CrossRef] [PubMed]
40. Vermeire, K.; Princen, K.; Hatse, S.; De Clercq, E.; Dey, K.; Bell, T.W.; Schols, D. CADA, a novel CD4-targeted
HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. Aids 2004, 18, 2115–2125. [CrossRef]
[PubMed]
41. Caffrey, M. HIV envelope: Challenges and opportunities for development of entry inhibitors. Trends Microbiol.
2011, 19, 191–197. [CrossRef] [PubMed]
42. Ferreira, L.G.; Dos Santos, R.N.; Oliva, G.; Andricopulo, A.D. Molecular docking and structure-based drug
design strategies. Molecules 2015, 20, 13384–13421. [CrossRef] [PubMed]
43. Anderson, A.C. The process of structure-based drug design. Chem. Biol. 2003, 10, 787–797. [CrossRef]
[PubMed]
44. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr. Computational methods in drug discovery.
Pharmacol. Rev. 2014, 66, 334–395. [CrossRef] [PubMed]
45. Stephen, A.G.; Worthy, K.M.; Towler, E.; Mikovits, J.A.; Sei, S.; Roberts, P.; Yang, Q.E.; Akee, R.K.;
Klausmeyer, P.; McCloud, T.G.; et al. Identification of HIV-1 nucleocapsid protein: Nucleic acid antagonists
with cellular anti-HIV activity. Biochem. Biophys. Res. Commun. 2002, 296, 1228–1237. [CrossRef]
46. Rein, A.; Henderson, L.E.; Levin, J.G. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins:
Significance for viral replication. Trends Biochem. Sci. 1998, 23, 297–301. [CrossRef]
47. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape
on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959–5967. [CrossRef] [PubMed]
48. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of
drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130–4146. [CrossRef]
[PubMed]
49. Li, S.; Satoh, T.; Korngold, R.; Huang, Z. CD4 dimerization and oligomerization: Implications for T-cell
function and structure-based drug design. Immunol. Today 1998, 19, 455–462. [CrossRef]
50. Gervaix, A.; West, D.; Leoni, L.M.; Richman, D.D.; Wong-Staal, F.; Corbeil, J. A new reporter cell line to
monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. USA 1997, 94, 4653–4658.
[CrossRef] [PubMed]
51. Chen, X.; Reynolds, C.H. Performance of similarity measures in 2D fragment-based similarity searching:
Comparison of structural descriptors and similarity coefficients. J. Chem. Inf. Comput. Sci. 2002, 42, 1407–1414.
[CrossRef] [PubMed]
52. Zhao, N.; Pei, S.N.; Parekh, P.; Salazar, E.; Zu, Y. Blocking interaction of viral gp120 and CD4-expressing T
cells by single-stranded DNA aptamers. Int. J. Biochem. Cell Biol. 2014, 51, 10–18. [CrossRef] [PubMed]
53. Lipinski, C.A. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004,
1, 337–341. [CrossRef] [PubMed]
54. Capasso, A.; Cerchia, C.; Di Giovanni, C.; Granato, G.; Albano, F.; Romano, S.; De Vendittis, E.; Ruocco, M.R.;
Lavecchia, A. Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25
dual specificity phosphatases and displaying in vitro efficacy against melanoma cells. Oncotarget 2015, 6,
40202–40222. [CrossRef] [PubMed]
Molecules 2018, 23, 3036 20 of 20
55. Lavecchia, A.; Di Giovanni, C.; Pesapane, A.; Montuori, N.; Ragno, P.; Martucci, N.M.; Masullo, M.;
De Vendittis, E.; Novellino, E. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by
structure-based virtual screening. J. Med. Chem. 2012, 55, 4142–4158. [CrossRef] [PubMed]
56. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS)
from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719–2740. [CrossRef]
[PubMed]
57. Capuzzi, S.J.; Muratov, E.N.; Tropsha, A. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay
Interference Compounds. J. Chem. Inf. Model. 2017, 57, 417–427. [CrossRef] [PubMed]
58. Li, X.; Ye, L.; Wang, X.; Wang, X.; Liu, H.; Qian, X.; Zhu, Y.; Yu, H. Molecular docking, molecular dynamics
simulation, and structure-based 3D-QSAR studies on estrogenic activity of hydroxylated polychlorinated
biphenyls. Sci. Total Environ. 2012, 441, 230–238. [CrossRef] [PubMed]
59. Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M.M.; Weissenhorn, W. Crystal structure of HIV-1
gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6, e1000880.
[CrossRef] [PubMed]
60. NCI Development Therapeutics Program. Available online: https://dtp.cancer.gov/organization/dscb/
obtaining/vialed.htm (accessed on 2 November 2017).
61. Enhanced NCI Database Browser 2.2. Available online: https://cactus.nci.nih.gov/ncidb2.2/ (accessed on 2
November 2017).
62. Li, X.; Ye, L.; Wang, X.; Wang, X.; Liu, H.; Zhu, Y.; Yu, H. Combined 3D-QSAR, molecular docking and
molecular dynamics study on thyroid hormone activity of hydroxylated polybrominated diphenyl ethers to
thyroid receptors β. Toxicol. Appl. Pharmacol. 2012, 265, 300–307. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
